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PSYCHIATRIC ETHICS AND EMERGING
ISSUES OF PSYCHOPHARMACOLOGY IN
THE TREATMENT OF DEPRESSION
John Alan Cohan*
INTRODUCTION
One of the principal purposes of psychiatric treatment is to do good
and avoid harm - the central aims of Hippocratic treatment ethics.' At
the same time, psychiatrists seek to help their patients feel better. In
fulfilling the latter function, there can be conflicts with the Hippocratic
duty. At times psychiatrists might abandon the ethical traditions of
their profession by prescribing "feel good" drugs that, while fulfilling
the goal of making the patient "feel" better, may be fundamentally
flawed in terms of doing harm in the long run, or even in the short run.
Many aspects of psychotherapy do not involve making the patient
"feel good." Psychoanalysis often involves varying degrees of intrusive
examination of a patient's innermost thoughts and motivations, and
the questions a therapist asks can often make patients feel
uncomfortable. The psychiatric profession justifies the painful aspects
of psychotherapy as being "worth it" in the same way that a painful
procedure, such as chemotherapy for cancer, is justified by the benefits
the treatment produces.
While the number of Americans who are in psychotherapy increased
slightly from 1987 to 1997, the average length of time patients spent on
the couch dropped significantly over the same period, with a
substantial increase in the proportion of patients receiving
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1. According to Robert M. Veatch, "the core of professional physician ethics,
the core of the Hippocratic tradition" is a commitment by physicians "to producing
good for their patient and to protecting that patient from harm." ROBERT M.
VEATCH, A THEORY OF MEDICAL ETHIcs 22 (1981).
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antidepressants and other psychiatric drugs.2 The trend to depart from
traditional psychotherapy was noted even before then by Anna Freud,
who remarked in a lecture delivered on the occasion of the 112th
anniversary of her father's birth, the extent to which people had
become alienated from psychoanalysis.3
In 1997, 9.69 million people visited psychotherapists - or 3.59% of
4the nation's population. The percentage of patients who saw
therapists for more than twenty sessions dropped to 10.26% in 1997
from 15.69% in 1987, and slightly over 33% attended only one or two
sessions.5 On the other hand, the percentage of patients who took
psychiatric medication increased to 61.52% in 1997 from 31.52% a
decade earlier.6 The most common diagnoses for patients who
received psychotherapy in 1997 were depression, manic-depression,
and other mood disorders.7 Almost 39.09% of patients were diagnosed
with depression, compared to 19.51% ten years earlier.8
When a patient has symptoms of depression, psychiatrists are faced
with many ethical dilemmas. In this article I will bring forth various
issues for consideration by the psychiatric community and other health
care professionals pertaining to the treatment of depression. I will
discuss emerging ethical problems with respect to the prescription and
use of antidepressants known as selective serotonin reuptake inhibitor
antidepressants, or "serotonin blocker" drugs (SSRIs) such as Prozac,
Paxil, Zoloft, Luvox, and Celexa. What is the truth regarding the side
effects of antidepressants? There are certain side effects admitted by
drug manufacturers, yet many other side effects discussed in scientific
studies and revealed through anecdotal evidence are cause for concern.
Some side effects have become separate mental syndromes in their
own right, listed in the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR), published by the American Psychiatric
Association. There are additional and serious side effects associated
with withdrawing from taking antidepressants. I will also discuss the
question of prescribing SSRIs for use by children, not only for
depression, but for what people have described as "attention deficit"
disorder. To what extent, if at all, is this "disorder" an abnormality
2. Erica Goode, Psychotherapy Shows a Rise Over Decade, But Time Falls,
N.Y. TIMES, Nov. 20, 2002, at A21.







that requires remediation through drugs? I will then turn to a
discussion of whether SSRIs are any more effective than placebos.
Various scientific studies have brought into doubt the efficacy of SSRIs
over placebos, based on reports from large samplings of patients. This
discussion brings to issue a further question of the paradigm, not often
questioned, that supposes mental abnormalities are tied to a
"biochemical imbalance" in the brain. To what extent is this true, or is
it somewhat of a myth? I will then turn to a discussion of the suicide
cases that have plagued the pharmaceutical firms that produce SSRIs,
and trace some of the lawsuits and report on their current status.
When unusual cases of suicide occur in people who previously had no
suicide ideation, and when the onset of suicidal symptoms occurs upon
taking SSRIs, there is indeed a significant concern of causation, not
merely correlation. My discussion will then turn to what has become a
popular culture topic in criminal law: "the Prozac defense." Various
criminal attorneys and a number of judges have taken this matter to
heart, opening a wedge that will no doubt continue to impact criminal
jurisprudence for some time to come. Next, I will discuss some of the
ethical concerns of studies that appear with respect to objectivity in
scientific journals. These issues include ghost-writing of scientific
articles by pharmaceutical companies, and the failure of scientific
authors to disclose significant financial ties to the firms for whose
drugs they are writing a favorable endorsement. Finally, I will turn to
a discussion of cosmetic pharmacology, questioning the ethics of
prescribing drugs simply to alter one's conception of self, to alter one's
personality, to get a competitive edge on others, or to provide other
cosmetic uses that will make one "normal," that is, competitive with
others who are also using drugs to enhance their apparent ability to
cope in the workplace and in other social settings. I will then provide
some concluding remarks, including a sense of how Aristotle, Bruno
Bettelheim, and Robert Nozick would regard the efforts to alter a
person's sense of well-being through drugs.
II. IS THERE A TREND TO TREAT DEPRESSION WITH
DRUGS RATHER THAN BY COGNITIVE
THERAPY?
Antidepressants known as selective serotonin reuptake inhibitor
antidepressants, or "serotonin blocker" drugs (SSRIs) such as Prozac,
Paxil, Zoloft, Luvox, and Celexa, are said to enhance serotonin
function. The chemical compound fluoxetine hydrochloride
("fluoxetine"), commonly known as Prozac, was developed by Eli Lilly
scientists in the 1970s, and was initially touted as a treatment for
20031
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depression. 9 This compound is believed to selectively inhibit the
brain's reuptake of serotonin, which is a neurotransmitter, a substance
that allows individual neurons to communicate with one another.
Because scientists believed there was a correlation between the level of
serotonin in the brain and mood, many claimed that this compound
might be efficacious in the treatment of depression. "By crossing the
synapses between neurons, serotonin and other neurotransmitters" are
said "to trigger neurual responses that ultimately influence thoughts
and emotions. 1 ° Prozac and other SSRIs are thought to inhibit the
central nervous system neuronal uptake of serotonin, thus assuring
that more of the neurotransmitter is available for triggering neurons."
These drugs are being prescribed not only for psychotic illnesses but
other conditions such as manic depression, Alzheimer's, personality
disorders, and nonpsychotic depression. 12 Prozac is also prescribed for
obsessive-compulsive disorder. Brain imaging shows that obsessive
compulsive disorder is associated with functional hyperactivity of the
caudate nucleus, a structure buried beneath the cerebral cortex. 3
Some researchers claim that the caudate is part of a subcortical circuit
that acts to screen out superfluous thoughts and impulses. The
subcortical circuit of obsessive compulsive disorder patients
malfunctions, allowing the repetitive thoughts to reach the cortex and
intrude themselves into one's conscious awareness. In addition,
patients with obsessive-compulsive disorder have altered serotonic
function compared with normal controls.'
4
It is now increasingly recognized that successful cognitive therapy
and successful pharmacological treatment produce similar changes in
the brains of patients with obsessive-compulsive disorder and other
disorders. For example, a study by Dr. Lewis Baxter at the UCLA
School of Medicine examined PET scans of patients with obsessive-
compulsive disorder who responded to either a reuptake inhibitor like
Prozac or cognitive behavior therapy after a ten-week period. 5 Both
9. UNITED STATES CONVENTION, INC., THE COMPLETE DRUG REFERENCE 580
(1991).
10. Michael D. Tomatz, Prozac: Is it the Next Rising Giant in Products
Liability?, 12 REV. LITIG. 704, 705 (1993).
11. Tomatz, supra note 10.
12. See Alex Berenson, Trial Lawyers Are Now Focusing On Lawsuits Against
Drug Makers, N.Y. TIMES, May 18, 2003, at Al.
13. Id.
14. Id.
15. Richard A. Friedman, Like Drugs, Talk Therapy Can Change Brain
Chemistry, N.Y. TIMES, Aug. 27, 2002, at F5.
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patient groups showed virtually identical changes in their brains,
namely decreases in the activities of the caudate nuclei.
Studies of patients with depression, reported in The Archives of
General Psychiatry, showed similar results. 16 Two studies compared
the effects of interpersonal psychotherapy with an antidepressant on
brain function, as observed in PET scans. In one study, one group of
depressed patients received interpersonal therapy, a short-term talk
treatment that focused on the effects of social relationships and major
life events on mood. Another group of depressed patients received an
SSRI, Paxil, in a twelve-week trial. The depressed patients who
responded to either treatment had nearly identical changes in the
abnormally high activity seen in the prefrontal cortex before
treatment. 17 In the second study, one group of depressed patients
received interpersonal therapy and another group received Effexor, an
antidepressant that enhances both serotonin and norepinephrine, and
there were similar, although not identical results.18
Based on these and other similar studies, the question arises that if
cognitive therapy, which focuses on changing distorted patterns of
thinking, results in the enhancement of neurotransmitter serotonin,
whose activity is often abnormal in people with obsessive-compulsive
disorder and depression, then why not bypass such therapy altogether
and achieve the "same" result, that is, the same changes toward normal
brain functioning, by pharmacological means?' 9
The answer can be seen in the statistics: Last year over 15 million
prescriptions were written for the two leading antipsychotic drugs,
Zyprexa and Risperdal20 "National sales of antipsychotic medications
reached $6.4 billion in 2002, making them the fourth-highest-selling
16. Id.
17. Id.
18. Id. This second study showed that patients "with interpersonal therapy but
not Effexor also had activation of a brain area called the cingulate gyrus, which
responds to serotonin in the brain and has a role in regulating mood." Id.
19. The work of Dr. Eric Kandel, a Nobel Prize-winning psychiatrist and
neurobiologist, showed that, with respect to the well-mapped nervous system of
sea slugs, learning leads to the production of new proteins and, in turn, to the
remodeling of neurons. Sea slugs exposed to the controlled-learning condition
that produced long-term memory ended up with double the number of neuronal
connections as the untrained animals. The implication of this and similar studies
for humans is that learning literally changes the structure and function of the brain.
Id.
20. See Erica Goode, Leading Drugs for Psychosis Come Under New Scrutiny,
N.Y. TIMES, May 20, 2003, at Al.
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drugs, behind cholesterol-lowering drugs, ulcer drugs and
antidepressants ....
III. WHAT IS THE TRUTH REGARDING SIDE EFFECTS
OF ANTIDEPRESSANTS?
The maxim primum non nocere is usually applicable to the
physician-patient relationship where the harms to be avoided are side
effects, complications, or other adverse medical events that could
involve damage or injury that are more or less directly attributable to
medical acts.
Some of the nation's leading trial lawyers are sponsoring
complicated and well-financed plaintiffs' suits against drug
manufacturers, claiming that the companies have hidden the addictive
dangers and side effects of antidepressant drugs.2  Lawyers involved in
current litigation claim that pretrial discovery reveals that some
companies have hidden the serious risks of not only psychotropic
medications, but of such popular drugs as Baycol, a cholesterol-
lowering drug. 3
Researchers are increasingly questioning whether antidepressants
are as effective or as benign as originally advertised, and whether the
benefits of these drugs are outweighed by their side effects. There is a
growing consensus that serious side effects are commonplace,
particularly in the form of Type II and Type I diabetes, hyperglycemia,
and excessive weight gain.24
The fact that a drug is approved for marketing by the FDA does not
in fact mean that the drug is truly safe and efficacious, but simply that
the drug meets minimal standards addressed by the FDA. Often the
evidence of side effects emerges well after a drug enters the
marketplace. The reporting of side effects after a drug is marketed is
only tentative because it is voluntary on the part of doctors, making it
hard to know what the true numbers are. According to the FDA, the
reports it receives on a drug's side effects after a drug is marketed
represent perhaps ten percent of the actual number of adverse
reactions.25
21. Id.
22. See Alex Berenson, supra note 12.
23. See id.
24. See id. In Japan and Europe some drugs, including Zyprexa and Seroquel,
already carry warning labels warning about the associated risk of diabetes. See id.
25. See Erica Goode, supra note 20.
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The Supreme Court has held that the regulation of product safety in
products liability cases is a matter of state prerogative, so that a drug
company's approval by the FDA is not dispositive of any legal issues
26pertaining to products liability.
A. Side Effects Admitted by Drug Manufacturers
The list of side effects admitted by the drug manufacturers is
staggering. For example, Eli Lilly's warnings indicate a range of side
effects including the development of restlessness, gritting of teeth,
tremors, decreased sexual interest, seizures, and more. Under the
"PRECAUTIONS" section of the company's description of Prozac on
its website, insomnia was reported by twelve percent to thirty percent
of patients, depending on whether they were taking the drug for
depression, obsessive compulsive disorder, or bulimia; and altered
appetite and weight, including significant weight loss, was noted
particularly in underweight depressed or bulimic patients, ranging
from eleven percent to seventeen percent, depending on the condition
for which the patient was being treated. Activation of
mania/hypomania as well as seizures was noted in only 0.1% to 0.2% of
patients.27
Additional side effects, not mentioned in the company's literature,
are nonetheless well documented. It is well established that
"prolonged treatment with any of the classes of antidepressants causes
changes in brain tissue, including a decreased number of receptors for"
serotonin.2 Some theorists claim that it is this deterioration of brain
cells, not the drug itself, which may actually result in an antidepressant
effect.29 In addition, a recent study raises the possibility that even some
30of the newer psychiatric drugs are linked to pancreatitis.
Various lawsuits claim that Lilly intentionally marketed a high
dosage of Prozac. "[D]uring the clinical trials, Lilly scientists proposed
26. Blowers v. Eli Lilly & Co., No. CVO0 00008 ACK FlY 927 (D. Haw. filed),
available at www.justiceseekers.com/files/NLPPOOOOO/013.pdf (last visited Feb. 8,
2004) [hereinafter Blowers Complaint].
27. ELI LILLY & CO., PROZAC DESCRIPTION 9-10, at http://pi.lilly.com/prozac.
pdf (last visited Feb. 8, 2004) [hereinafter PROZAC DESCRIPTION].
28. Cathrine M. Vale, The Rise and Fall of Prozac: Products Liability Cases
and "The Prozac Defense" in Criminal Litigation, 12 ST. Louis U. PUB. L. REV.
525, 528 (1993); see O.S. RAY & CHARLES KSIR, DRUGS, SOCIETY & HUMAN
BEHAVIOR (6th ed. 1993).
29. Vale, supra note 28, at 528.
30. See Goode, supra note 20.
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a 5 or 10 mg dose regimen [of Prozac], but they were countermanded
by the CEO of the company."31 Thus, the company, in its fervor to
produce a best seller, marketed a twenty milligram, "one size-fits-all"
pill so that prescribing physicians would not have to worry about dose
selection and so that patients would get a "quicker hit."32 One of the
concerns of this large dose is that some individuals simply do not
metabolize Prozac as well most people do, and the rapid accumulation
of Prozac in the body can exacerbate side effects.33 Later, Lilly
manufactured a ten milligram pill, but by that time the twenty
milligram dose had been established as the "standard" dose for
physicians to prescribe. 4 The significance of this is that adverse drug
reactions are generally dose related.35 Moreover, this plays into the
hands of critics who deride a trend in psychiatry to over-medicalize,
and to invent new categories of mental illness: "This has led to the risk
of inappropriate medicalization, with associated abuse of drug
treatment so as to achieve societal control. 3 6  Lilly could have
manufactured a lower, safer dose in a "once a week" design, something
that appeared to be effective in a Lilly-sponsored trial in the United
Kingdom. 37 Lilly, however, did not start marketing a once-a-week
Prozac until its patent rights had come to a close and other
manufacturers were poised to market a generic formulation of
fluoxetine hydrochloride.38
B. Side Effects Reported by Anecdotal Evidence and Scientific
Journals
Anecdotal evidence, not acknowledged by pharmaceutical firms, as
well as studies in peer review science journals, also point to a host of
additional side effects associated with the use of SSRIs. Such
anecdotal evidence consists of reports of mind racing, inability to
31. Cole v. Eli Lilly & Co., No. 02-2484-DV J 13 (W.D. Tenn. Filed June
2002), available at www.justiceseekers.com/files/NLPOOOO0/060.pdf (last visited
Feb. 8, 2004) [hereinafter Cole Complaint].
32. Id.
33. Blowers Complaint, supra note 26, at 20.
34. See id.
35. See id. at 15.
36. PAUL BROWN, Ethical Aspects of Drug Treatment in PSYCHIATRIC ETHICS
167, 171(Sidney Bloch & Paul Chodoff eds., 2d ed. 1991).
37. Cole Complaint, supra note 31, 14.
38. Id.
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control thoughts, panic attacks, hot surges, nightmares, lack of
empathetic feelings or emotions, feelings like being a zombie,
numbness in limbs, dizziness, feeling disconnected from others, heart
palpitations, uncontrollable flashes of memories and images from the
past, agoraphobia, feeling drugged out, feeling urges to jump out of
fast moving cars, extreme head pain, increased depression, nose
bleeds, loss of sex drive, memory loss, sudden and excessive weight
gain, hating people, not wanting to be around people, tremors, sudden
jerky movements of muscles, inability to focus or concentrate,
breathing difficulty, uncontrollable bouts of anger, self-mutilation, and
much more. 9 In addition, the antidepressant Serzone, which has been
banned in Europe, is now the subject of a campaign by a consumer
advocacy group known as Public Citizen, to remove it from sale in the
United States because of cases of deadly liver failure among users of
the drug.4 A new analysis of the FDA Adverse Event Reports
Database found that from April 1, 2002, through May 12, 2003, there
were thirty-three additional reports of liver failure - including nine
deaths - for a total of fifty-five patients with liver failure. 4' The
Canadian government has announced that it has now banned the
drug.42
A 1998 article in the Journal of Psychopharmacology reported that
when taken in tandem with other substances that increase serotonergic
activity in the brain, Prozac can lead to a condition called serotonin
syndrome, which is characterized by cognitive behavioral changes
(confusion, hypomania, and agitation) as well as delusions and
hallucinations. 43 "Neurological disorders including disfiguring facial
and whole body tics, indicating potential brain damage, are an
increasing concern with patients on the drugs .... With related drugs
targeting serotonin, there is evidence that they may effect a 'chemical
lobotomy' by destroying the nerve endings that they target in the
39. See Real Side Effects of SSRI's, at http://www.prozactruth.com/sideeffects.
htm (last visited Feb. 8, 2004).
40. See Associated Press, Testimony on Antidepressant, N.Y. TIMES, Oct. 30,
2003, at A25.
41. See Public Citizen Renews Call to Ban Antidepressant Serzone; Canadian
Ban, New Data Strengthen Case, available at www.citizen.org/pressroom/release.
cfm?ID=1567 (last visited Feb. 8, 2004).
42. See id.
43. Roger M. Lane, SSRI-Induced Extraphramidal Side-effects and Akathisia:
Implications for Treatment, 12 J. PSYCHOPHARMACOLOGY 192,203 (1998).
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brain." 4 Peter Breggin, M.D., a well-known critic of SSRIs, says of
these minor tranquillizers, "As with most psychiatric drugs, the use of
the medication eventually causes an increase of the very symptoms
that the drug is supposed to ameliorate .... 45
Prozac and other SSRIs, which the psychiatric profession initially
prescribed for symptoms of depression, can often create a worsening of
depression. "In a seemingly paradoxical effect, antidepressants can
cause or worsen depression. In controlled clinical trials for Prozac...
depressed patients taking Prozac attempted suicide more frequently
than depressed patients taking placebo (sugar pill) or older
antidepressants." 46 It has also been noted that one of the effects that
Prozac has on a person's mood is to diminish one's sense of rejection,
sensitivity, and vulnerability; as well as enhancement of hedonistic
behavior. These traits, if multiplied on a collective level could
depersonalize society so that people will be motivated only by self-
interest and become disconnected from a larger sense of community.
The suffering that patients might feel with depression or with other
disabling symptoms "cannot be dulled without harming other functions
such as concentration, alertness, sensitivity, and self-awareness., 47 The
authors of one study say: "Do not let anyone pressure you into
starting or continuing psychiatric drugs. As a competent adult, you
have the ethical and legal right to make your own decisions about
taking psychiatric drugs."
The July 15, 2002 Newsweek magazine reported that a new study by
University of Connecticut psychologist Irving Kirsch titled "The
Emperor's New Drugs" found that antidepressant drugs "may have no
meaningful pharmacological effect at all., 49 Kirsch pooled data from
thirty-eight studies on six antidepressant drugs approved by the FDA
(Prozac, Zoloft, Paxil, Serzone, Celexa, and Effexor) and found "that
people who got placebos fared almost as well as those getting real
drugs."50 He found that on the fifty-point Hamilton Depression Scale,
44. JOSEPH GLENMULLEN, PROZAC BACKLASH: OVERCOMING THE DANGERS
OF PROZAC, ZOLOFr, PAXIL, AND OTHER ANTIDEPRESSANTS WITH SAFE,
EFFECrIVE ALTERNATIVES 8(2000).
45. PETER BREGGIN, TOXIC PSYCHIATRY 246 (1991).
46. Id.
47. Id. at 36.
48. PETER R. BREGGIN, M.D. and DAVID COHEN, Ph.D., Your Drug May Be
Your Problem: How and Why to Stop Taking Psychiatric Drugs 29 (1999).
49. David Noonan & Geoffrey Cowley, Prozac vs. Placebos, NEWSWEEK, July
15, 2002, at 48-49.
50. Id.
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people getting real drugs improved ten points, while people getting
placebos improved eight points. The article quotes clinical
psychologist David Antonuccio of the University of Nevada School of
Medicine as saying, "One day we may look back and marvel at the
stroke of marketing genius that led to calling these medications
antidepressants in the first place."'" In fact, as early as 1994 Newsweek
had already reported that "[Prozac] ... and its chemical cousins Zoloft
and Paxil are no more effective than older treatments for
depression. ,12
The author of Listening to Prozac, Peter D. Kramer, who is now a
clinical professor of psychiatry at Brown University, said in a letter to
the New York Times:
[Your article] may give the misimpression that my 1993 book,
"Listening to Prozac," claimed that the new antidepressants
were miracle drugs. In fact, I wrote that Prozac was no more,
and perhaps less, effective in treating major depression than
prior medications. The book was early to identify Prozac's
undesirable effects, including 'burnout' and sexual dysfunction.
I argued that the theories of brain functioning that led to the
development of Prozac must be wrong or incomplete.53
A recent article in Barron's reported that "Antidepressant sales in
the U.S. jumped to $12.5 billion in 2001 from $1.5 billion in 1991, making
them the largest profit driver for the pharmaceutical industry in the
1990s" and "[b]etween 1991 and 2001, global sales of antidepression
drugs rose ten-fold, to over $11 billion, making this sector the drug
industry's chief profit driver in the decade." The article cited Forrest
Laboratories, which got sixty-eight percent of its $1.6 billion in revenue
in 2001 from its new antidepressant, Celexa. The article stated, "Paxil,
the No. 1 drug on the market... brought in $2.7 billion in revenues last
year."55  The article goes on to say, "Depression is caused by an
imbalance of chemicals in the brain," which is asserted as a claim
without argument.6 Then the article claims, inconsistently:
Ironically, clinicians still don't understand exactly how these
drugs work. For while they increase the levels of serotonin in
51. Id.
52. Geoffrey Cowley, The Culture of Prozac, NEWSWEEK, Feb. 7, 1994, at 41.
53. Peter R. Breggin, Fighting the Darkness in the Mind, N.Y TIMES, July 7,
2002, §4, at 8.
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the brain very quickly, they can take three to six weeks to kick in
and start lifting depression .... What's more, it's a common
finding that between 30% and 50% of patients taking any one of
the new antidepressants fails to get any benefit from that
particular drug. They must try a second, and maybe even a third,
before they find one that works.57
C. Side Effects That Have Become Separate Mental Syndromes Listed
in the DSM-IV-TR
The Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV-TR), published by the American Psychiatric Association, includes
several syndromes that are neuroleptic-induced, that is, side effects
that develop within a few days of starting or rapidly increasing the dose
18of neuroleptic medications. Neuroleptic medications are defined as
antipsychotropic drugs as well as major tranquillizers.5 9 A large
number of drugs are classified as neuroleptic, including numerous
antidepressants such as Prozac, Luvox, Effexor, Xanax, and numerous
other drugs.60 These neuroleptic drugs are known to induce detailed
side effects that are serious enough that the American Psychiatric
Association has seen fit to specify these side effects as separate
syndromes under the DSM-IV-TR. In other words, the psychiatric
community is sufficiently familiar with the side effects of
antidepressant drugs so that they have defined separate mental
syndromes that are caused by the very drugs prescribed for the "cure"
of other mental syndromes. Bizarre as it seems, the American
Psychiatric Association has decided to classify the side effects of taking
various psychiatric drugs as separate mental syndromes in their own
right. One of the results of classifying the side effects of psychiatric
drugs as separate mental syndromes is this: These side effects,
constituting separate mental syndromes, may be treated as further
symptoms that merit further treatment to counteract the drug-induced
symptoms - with further drugs!
I will briefly discuss these well-established side effects, which as
mentioned have become separate mental syndromes in their own right.
57. Id.
58. See, e.g., AM. PSYCHIATRIC ASS'N, DIAGNOSTIC AND STATISTICAL MANUAL
OF MENTAL DISORDERS § 333.7 (4' ed. Text rev. 2000) [hereinafter DSM-IV-TR].
59. See COMPREHENSIVE HANDBOOK OF PSYCHOPATHOLOGY 804 (Patricia B.
Sutker & Henry E. Adams eds., 3d ed. 2001).
60. See id. at 805, tbl. 3.
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These side effects, known as extrapyramidal effects, result from
dopamine blockade, and are divided into four major categories:
1. Neuroleptic-induced Acute Dystonia61 occurs within seven days
after administering the drug. This involves abnormal postures or
muscle spasms that develop in association with use of the drug.
Symptoms include abnormal positioning of the head and neck, spasms
of the jaw muscles, impaired swallowing, speaking, or breathing
(potentially life-threatening), and thickened or slurred speech. Fear
and anxiety often accompany the onset of this dystonia. Patients often
mistakenly regard the symptoms as part of their mental disorder.
2. Neuroleptic-Induced Acute Akathisia 62 is a very unpleasant
sensation of restlessness, resulting in an inability to stay still,
characterized by fidgety movements, swinging of the legs while seated,
pacing to relieve restlessness, the inability to stand still for at least
several minutes, and a sense of inner restlessness. SSRI-induced
akathisia is "an internal sensation of agitation or discomfort that drives
a person to move about, and also to lose impulse control. During
akathisia, the inner sense of agitation includes many unusual physical
feelings such as electricity in the head or body." 63 Symptoms can occur
within four weeks of initiating the drug or increasing the dose, or
following the reduction or withdrawal of the medication. The DSM-
IV-TR says that the subjective distress can be severe enough to result
in patients increasing their medication dose, or to result in aggression
or suicide attempts.64 The symptoms of akathisia range from twenty-
five percent to seventy-five percent in patients taking neuroleptic
drugs. These symptoms persist for as long as the medication is
continued, and can persist after the drugs are stopped. "Serotonin-
specific reuptake inhibitor antidepressant medications may produce
akathisia that appears to be identical in phenomenology and treatment
response to Neuroleptic-Induced Acute Akathisia." 65 Some studies
indicate that some of the newer drugs carry a lower risk of tardive
dyskinesia, but other studies claim that overall, side effects are about
the same.66 A study financed by the British government and published
in the British Medical Journal in 2000, claimed that there was no
61. See DSM-IV-TR, supra note 58, § 333.7.
62. See id. § 333.99.
63. Peter R. Breggin, Paxil Withdrawal Suit Resolved, in PSYCHIATRIC DRUG
FACTS, at http://www. breggin.com/paxilwithdrawalsuitl.html (last visited Feb. 8,
2004) [hereinafter Paxil Withdrawal Suit Resolved].
64. See DSM-IV-TR, supra note 58, § 333.99.
65. Id.
66. See Paxil Withdrawal Suit Resolved, supra note 63.
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difference in effectiveness between the newer generation of
antipsychotic drugs and older drugs.67
3. Neuroleptic-Induced Tardive Dyskinesia 68 involves abnormal,
involuntary movements of the tongue, jaw, trunk, or extremities as side
effects of neuroleptic medication. The symptoms can occur both at the
onset of taking the medication or with the withdrawal of the
medication. The symptoms are worsened by stimulants and emotional
distress. Psychiatrists are advised that the symptoms can be reduced
by "increased doses of neuroleptics or sedatives. ' '69 About twenty
percent to thirty percent of patients are subject to these symptoms.
With older patients, the norm is about fifty percent.
4. Medication-Induced Postural Tremor 7 is a postural tremor
developed in association with the use of antidepressants, other
neuroleptic medications, and other drugs. The tremor involves a
regular, rhythmic oscillation, most commonly of the hands and fingers,
head, mouth, or tongue, with a frequency of eight and twelve cycles
per second.
In addition, the DSM-IV-TR lists a disorder known as Substance-
Induced Anxiety Disorder,7' which involves anxiety symptoms evoked
by various medications, including antidepressant drugs. Symptoms
under this disorder include panic attacks and obsessions or
compulsions, and the "disturbance causes clinically significant distress
or impairment in social, occupational, or other important areas of
functioning. ,
72
There is also what is known as SSRI-induced obsessive-compulsive
behavior that motivates violence toward oneself or others.73
Thus, the DSM-IV-TR directly acknowledges a multiplicity of side
effects serious enough to warrant separate categories of discussion in
the manual, while the warnings that accompany the packaging of these
drugs fail to provide this information. Many doctors do not realize
that the toxic side effects of SSRIs can surface just after the first or
second dose, while the "therapeutic effect" of any antidepressant
usually takes several weeks or more to kick in.74
67. See id.
68. See DSM-IV-TR, supra note 55, § 333.82.
69. Id. (emphasis added).
70. Id. § 333.1.
71. Id. at 479.
72. Id. at 483.
73. See Paxil Withdrawal Suit Resolved, supra note 63.
74. Id.
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D. Side Effects Associated With Withdrawing from the Drugs
In addition to side effects of the kinds discussed above, there is a
separate type of side effect associated with withdrawal from the use of
SSRIs. Among the lawsuits against drug manufacturers of Prozac and
other SSRIs are allegations that the drug companies failed to warn the
public about the dangers of withdrawing from antidepressant drugs.
According to a growing consensus of medical experts, all of the SSRIs
can cause serious withdrawal reactions. A common mantra concerning
psychiatric drugs is this: "All psychiatric drugs can cause problems
during withdrawal,"75 and the longer a patient takes a psychiatric drug,
the more difficult withdrawal will be. The earliest mention of the
dangers of SSRI withdrawal appear to have been expressed by Peter
R. Breggin, M.D., in his book, Talking Back to Prozac,76 and in two
more recent books, Brain-Disabling Treatments in Psychiatry" and The
Antidepressant Fact Book.78
Paxil, because of its intense impact and short duration of action,
causes the most severe withdrawal reactions.79 In December 2001,
most likely in response to a pending settlement of a California lawsuit,
Glaxo SmithKline revised its label for Paxil with a specific mention of
the danger of Paxil's withdrawal reactions. 80 The revised label refers to
"discontinuation" rather than "withdrawal" symptoms.
Discontinuation is an industry euphemism for withdrawal that avoids
the negative connotations associated with addiction, dependency, or
withdrawal syndrome.8' "By using the term discontinuation instead of
withdrawal, the drug company obscures the potential severity of these
symptoms and their tendency to force patients to continue taking the
drug." 82 Withdrawal symptoms of SSRIs include abnormal dreams,
paresthesia (abnormal sensations), sensory disturbances such as
electric shock sensations, agitation, anxiety, nausea, sweating, painful
75. BREGGIN & COHEN, supra note 48, at 16.
76. See generally PETER R. BREGGIN, M.D. & GINGER BREGGIN, TALKING
BACK TO PROZAC (1994).
77. See generally PETER R. BREGGIN, M.D., BRAIN-DISABLING TREATMENTS IN
PSYCHIATRY: DRUGS, ELECTROSHOCK AND THE ROLE OF THE FDA (1997).
7& See generally PETER R. BREGGIN, M.D., THE ANTIDEPRESSANT FACT BOOK
(2001).
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internal sensations, various manifestations of emotional distress, and
dizziness.83 Of particular concern are the withdrawal symptoms of
anxiety and agitation, as these can contribute to aggressive, violent, or
suicidal behavior.
Many more people are taking prescription drugs than used to be the
case. No medicine is completely safe for everyone. Even the safest
drugs have side effects. Because clinical trials for new drugs are
conducted on only a few thousand subjects, the tests do not always
discover rare but danger side effects that might affect one in a million
users. Generally, the number of reported cases of serious side effects
is relatively small. Quite plausibly, drug makers may find it strategic to
introduce a "new generation" of psychotropic drugs, claiming some
improvement, just in time to accommodate the fact that the patent on
the older formula is about to expire.
IV. THE RISKS ASSOCIATED WITH SSRI USE BY
CHILDREN
The risks become a more pressing issue when SSRIs are prescribed
for children.
The number of children and adolescents who take a wide range of
psychiatric drugs more than doubled between 1987 and 1996, according
to researchers at the University of Maryland who studied 900,000
children and adolescents. 84  According to the study, the most
commonly prescribed psychiatric drugs for children are
antidepressants and Ritalin (for attention deficit disorder).85  In
addition, the drug clonidine is often prescribed for children as an
antihypertensive for the insomnia produced by Ritalin or other
stimulants.86  Other conditions for which pediatricians and child
psychiatrists are increasingly turning to pharmacology include severe
anxiety, obsessive disorder, manic depression, and other conditions.87
Earlier this year, the FDA approved Prozac to treat depression in
88children from ages seven to seventeen. The problem with this trend is
83. Id.
84. Erica Goode, Study Finds Jump in Children Taking Psychiatric Drugs,






that little research is available to show the long-term effects of
psychiatric drugs on children, and this concern is exacerbated by the
fact that animal studies suggest that some psychiatric drugs have
lasting effects on the brain when given before puberty.89
Recently, British drug regulators sent a letter to doctors and other
health care professionals advising against the use of all anti-
depressants except Prozac for the treatment of depressed children
under eighteen.90 The government regulators contend that the safety
and effectiveness of SSRIs indicates that their benefits do not outweigh
their potential risks.9'
Moreover, little research is available to show whether psychiatric
drugs are being prescribed in a responsible manner, or whether they
are being over-prescribed, given that health insurance companies are
known to be reluctant to pay for "talk" therapy and other non-
medication treatments for the amelioration or cure of mental illness
symptoms. 2 Finally, there is little guidance in establishing the effective
doses and duration of psychiatric medications for children.93 I believe
that it is a disturbing medical trend to medicate children with serious,
or perhaps not-so-serious, mental health needs, particularly in the face
of limited scientific and clinical data that address the potential lasting
impacts on the brain of children.
There has been a 1,100% increase in Attention Deficit Hyperactivity
Disorder (ADHD) diagnoses in American children between 1987 and
2001. 4 Many claim that it is invalid to classify ADHD as a mental
illness in the first place. For example, the Commission on Human
89. Id.
90. See Erica Goode, British Warning on Antidepressant Use for Youth, N.Y.
TIMES, Dec. 11, 2003, at Al. For a summary of the British government drug
agency's findings, see MEDICINES AND HEALTHCARE PRODUCTS REGULATORY
AGENCY [MHRA], SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs):
OVERVIEW OF REGULATORY STATUS AND CSM ADVICE RELATING TO MAJOR
DEPRESSIVE ORDER (MDD) IN CHILDREN AND ADOLESCENTS INCLUDING A
SUMMARY OF AVAILABLE SAFETY AND EFFICACY DATA, available at http://
medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/ssrioverview
101203.htm (last visited Feb. 8, 2004) [hereinafter MHRA].
91. See Goode, supra note 90, at Al; MHRA, supra note 90.
92. See Goode, supra note 90, at Al; MHRA, supra note 90.
93. See Goode, supra note 90, at Al; MHRA, supra note 90.
94. CITIZENS COMMISSION ON HUMAN RIGHTS INTERNATIONAL, CHILD
PSYCHIATRY PUT ON NOTICE DUTCH COMMISSION FINDS PSYCHIATRIC CLAIM IS
FALSE-ADHD IS NOT A BRAIN DISORDER, available at http://www.prozactruth.
com/addadhd.htm (last visited Feb. 8, 2004).
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Rights argues that it is fraudulent for psychiatrists to claim that
ADHD is neurobiological.9 The DSM-IV-TR itself declares that "it
must be admitted that no definition adequately specifies precise
boundaries for the concept of 'mental disorder."' 96 The DSM-IV-TR
further admits that attention-deficit is a commonplace occurrence in
most people, stating as follows: "Although most individuals have
symptoms of both inattention and hyperactivity-impulsivity, there are
some individuals in whom one or the other pattern is predominant. '" 97
The psychiatric community admits that a diagnosis of ADHD is in
effect not susceptible to scientific confirmation. The Associated
Laboratory findings section states, "There are no laboratory tests that
have been established as diagnostic in the clinical assessment of
Attention-Deficit/Hyperactivity Disorder. 98  The discussion further
states:
It is very unusual for an individual to display the same level of
dysfunction in all settings or within the same setting at all times.
Symptoms typically worsen in situations that require sustained
attention or mental effort or that lack intrinsic appeal or novelty
(e.g., listening to classroom teachers, doing class assignments,
listening to or reading lengthy materials, or working on
monotonous, repetitive tasks). Signs of the disorder may be
minimal or absent when the person is under very strict control,
in a novel setting, is engaged in especially interesting activities,
in a one-to-one situation (e.g., the clinician's office), or while the
person experiences frequent rewards for appropriate behavior.99
And the DSM-IV-TR discussion suggests that the "disorder" goes
away as children mature:
As children mature, symptoms usually become less conspicuous.
By late childhood and early adolescence, signs of excessive gross
motor activity (e.g., excessive running and climbing, not
remaining seated) are less common, and hyperactivity symptoms
may be confined to fidgetiness or an inner feeling of jitteriness
or restlessness. 10
It seems to fly against common sense to claim that something is a
mental disorder if the symptoms go away as the child matures. What
are we to see next? Perhaps the next edition of the DSM will
95. Id.
96. See DSM-IV-TR, supra note 58.
97. Id. at 80.
98. Id. at 81.
99. Id. at 79.
100. Id. at 81-82.
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categorize the tendency of prepubescent boys' voices to undergo
changes in tone as a mental syndrome, notwithstanding that they, too,
"outgrow" the "symptoms." In light of the DSM-IV-TR's own
admissions, it would seem to be a common sense matter to place
children who really have a problem with attention-deficit and
hyperactivity in settings where they are least likely to manifest the
"disorder," and to give them material that has an intrinsic appeal
rather than material that lacks intrinsic appeal in their daily activities.
Moreover, if children display symptoms of hyperactivity that becomes
a problem for others around them, this may plausibly be, very simply
put, an occasion to exercise proper control over them by parents and
teachers. The signs of the "disorder" may go away when children are
under appropriate classroom discipline or are engaged in especially
interesting activities.
V. ARE SSRIs SIGNIFICANTLY MORE EFFECTIVE THAN
PLACEBOS?
It is one thing to examine whether a drug is safe, and an entirely
separate matter to determine whether a drug is therapeutically
effective. Some scientists think that the efficacy of antidepressant
drugs is extremely dubious, and that "no significant progress in the
pharmacological treatment of depression has occurred since the
introduction of imipramine in 1958." '°1 This notion is echoed by Peter
Breggin, M.D., who famously asserts:
The most fundamental point to be made about the most
frequently used major antidepressants is that they have no
specifically antidepressant effect. Like the major tranquilizers to
which they are so closely related, they are highly neurotoxic and
brain disabling, and achieve their impact through the disruption
of normal brain function.... Only the "clinical opinion" of drug
advocates supports any antidepressant effect."
Even lithium, which is said to be helpful for people whose mood
repeatedly changes from manic to depressive and back again, and
widely used psychiatric drugs called minor tranquillizers, including
Valium, Librium, Xanax, and Halcion, are supposed to provide a
calming, anti-anxiety, panic-suppression remedy, but many regard
101. RICHARD ABRAMS, M.D., ELECTROCONVULSIVE THERAPY 7 (1988).
102. PETER R. BREGGIN, M.D., PSYCHIATRIC DRUGS: HAZARDS TO THE BRAIN
160, 184 (1983).
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them to be ineffective and dangerous. A 1993 Consumer Reports
article stated that these so-called minor tranquillizers do not cure
anything, but are principally brain-disabling drugs that produce in the





Many have questioned whether the taking of antidepressants is any
better than taking a placebo. According to critics of antidepressant
drugs, FDA studies on Prozac "underscored the drug's lack of
effectiveness and recent analyses of literature indicate that
antidepressants in general are no better than placebo."' 4 In an article
entitled No Prescription for Happiness, journalist Thomas Moore
reviewed the FDA studies in connection with the approval of Prozac,
and said:
Lilly [manufacturer of Prozac] had conducted 10 such clinical
trials for Prozac, according to FDA records. However, in six of
these trials no measurable overall difference could be detected
between those treated with Prozac and those who got the
placebo.... Failure to produce a measurable effect is a routine
event in the testing of drugs for depression1
While about sixty percent of patients report that they experience
relief of their symptoms of depression, bulimia, and obsessive-
compulsive disorder - the three main illnesses for which Prozac and
other anti-depressant drugs are approved - a small but significant
percentage of patients actually become worse on Prozac.'
6
In one study, researchers found that Zoloft, a commonly prescribed
antidepressant, was only ten percent more effective than placebos for
treatment of depression in children and teenagers, a margin deemed to
be rather small.1°7 A researcher involved in the findings said that the
large number of subjects who improved while taking placebos "does
seem to support the idea that children and adolescents may be more
responsive to environmental effects."' 8
Another comment on the placebo effect is noted as follows:
103. LAWRENCE STEVENS, J.D., PSYCHIATRIC DRUGS: CURE OR QUACKERY?,
available at http://www.antipsychiatry.org/drugs.htm (last visited Feb. 8, 2004).
104. BREGGIN & BREGGIN, supra note 76, at 57.
105. Douglas A. Smith, Book Review, available at http://www.antipsychiatry.
org/br-pibp.htm (last visited Feb. 8, 2004) (reviewing COLIN A. Ross, M.D., &
ALVIN PAM, PH.D. ET AL., PSEUDOSCIENCE IN BIOLOGICAL PSYCHIATRY (1995)).
106. Vale, supra note 28, at 525.
107. Erica Goode, Researchers Find Zoloft, a Popular Antidepressant, to be
Effective in Treating Children, N.Y. TIMES, Aug. 27, 2003, at A18.
108. Id.
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Despite a hugely successful promotional campaign by drug
companies and biological psychiatry, the effectiveness of most or
all psychiatric drugs remains difficult to demonstrate. The drugs
often prove no more effective than sugar pills, or placebos - and
to accomplish even these limited positive results, the clinical
trials and data that they generate typically have to be statistically
manipulated.'09
According to some studies and anecdotal evidence, Prozac actually
is claimed to be effective in the treatment of a number of disorders
having nothing to do with depression, including body dysmorphic
disorder, trichotillomania (pulling out of one's hair), writer's block,
alcoholism, pathologic jealousy, attention deficit hyperactivity
disorder, panic disorder, premenstrual tension, chronic pain, dementia,
gambling, and fear of public speaking." Does it not seem odd that a
drug, originally approved as an antidepressant, has become a drug of
choice for a wide variety of completely unrelated disorders? How
could it be that a psychiatric drug designed for a specific treatment
would be equally suited for such an array of disorders - unless in fact
its effectiveness is the placebo effect?
The "biochemical imbalance" myth: There are various explanations
of why placebos would be just as effective as drugs for "treating"
certain symptoms. First, many disagree with the theory of the
biological causation of mental illnesses. There is a growing movement
to discredit the idea that depression or other mental disorders are the
result of a biological abnormality or a "chemical imbalance," rather
than being caused by events, environmental circumstances, or personal
relationships that have no basis in the annals of science."' That is,
many believe that the notion that numerous mental syndromes are
neurobiological diseases or based on brain dysfunction is just false.
Such critics argue that psychiatric disorders are caused by life
experience rather than by the theoretical biological abnormalities that
the pharmacology industry would want psychiatrists to believe. In
Pseudoscience in Biological Psychiatry, the authors, Colin A. Ross,
M.D. and Alvin Pam, Ph.D., claim that biological psychiatry, presently
the dominant force within the psychiatric community, relies on a
scientific methodology that is "sufficiently flawed as to call into doubt
109. BREGGIN & COHEN, supra note 48, at 37.
110. Colleen Cebuliak, Life as a Blonde: The Use of Prozac in the '90s, 33
ALBERTA L. REV. 611, 612-613 (1995).
111. See LAWRENCE STEVENS, J.D., THE MYTH OF BIOLOGICAL DEPRESSION,
available at http://www.antipsychiatry.org/depressi.htm (last visited Feb. 8, 2004).
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,,1 12the preponderance of its accepted findings .... In fact, the authors
find that
[t]he history of biological psychiatry can be depicted as a tale of
"promising" leads, closure on slender evidence, hyperbole as
initial reception to new work, and ultimately unproductive
results. . . . [Flollowing about a century of effort, a harsh
assessment would be that no substantive results have been
tendered for the pathogenesis of any major psychiatric
disorder."3
The authors claim that "biological psychiatry does not come close to
meeting scientific standards,"' 1 4 and that "[a]t the present time, there is
no proof that biology causes schizophrenia, bipolar mood disorder, or
any other functional mental disorder."'"5 The trouble with biological
psychiatry is that the locus of blame for disturbed behavior is the body
rather than the family, society, or other social conditions that give rise
to pathologies. "This perspective lets the social surround escape
unscathed from any blame or responsibility, no matter how much
psychological disorder is in its midst.""1
6
The controversial belief in biological causation has spawned the
growth of the pharmaceutical industry's otherwise unjustifiable
biological "treatments" for depression, based on the idea that
unhappiness is caused by biological malfunction rather than by life
experiences. Many claim that there is no convincing evidence that
depression is ever biologically caused."17 For example, in her book, The
Broken Brain: The Biological Revolution in Psychiatry, University of
Iowa psychiatry professor Nancy Andreasen, M.D., Ph.D., expresses
her skepticism this way: "The older term endogenous implies that the
depression 'grows from within' or is biologically caused, with the
implication that unfortunate and painful events such as losing a job or
lover cannot be considered contributing causes."" 8 A panel of experts
assembled by the U.S. Congress Office of Technology Assessment in
1992 discredited the theory that depression is "caused" by lowered
levels or abnormal use of the brain chemical serotonin, stating,
112. COLIN A. Ross, M.D. & ALVIN PAM, PH.D., PSEUDOSCIENCE IN
BIOLOGICAL PSYCHIATRY 8 (1999).
113. Id. at 42.
114. Id. at 69.
115. Id. at 90.
116. Id.
117. See STEVENS, supra note 111.
118. NANCY ANDREASEN, M.D., PH.D., THE BROKEN BRAIN: THE BIOLOGICAL
REVOLUTION IN PSYCHIATRY 203 (1984).
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"Currently, no clear evidence links abnormal serotonin receptor
activity in neurotransmitter levels or for disruption of normal receptor
activity.'"9
Adding to the chorus of concern about the medicalization of mental
disorders are Peter R. Breggin, M.D. and David Cohen, Ph.D., authors
of Your Drug May Be Your Problem: How and Why to Stop Taking
Psychiatric Drugs."2° The authors claim that no matter what one's
"psychiatric problem" may be, whether depression, manic-depression,
anxiety, or even schizophrenia, one is better off without psychiatric
drugs. They claim:
No psychiatric drug has ever been tailored to a known
biochemical derangement.... [N]o biochemical imbalances have
ever been documented with certainty in association with any
psychiatric diagnosis. The hunt goes on for these illusive
imbalances; but their existence is pure speculation, inspired by
those who advocate drugs. '
They further say:
Although medication advocates often speak with seeming
confidence about how psychiatric drugs can correct biochemical
imbalances in the brain, they are merely indulging in pure
speculation. There's little evidence for the existence of any such
imbalances, and no way to demonstrate how drugs would affect
them if they did exist. 2
Advocates of psychiatric drugs often claim that the medications
improve learning and the ability to benefit from psychotherapy,
but the contrary is true. There are no drugs that improve mental
function, self-understanding, or human relations. Any drug that
affects mental processes does so by impairing them."'
Critics also argue that no physical cause can be proven for today's
mental illnesses. The commonly prescribed psychiatric drugs appear to
disable the brain in a generalized way. None of today's psychiatric
drugs have the sort of specificity for depression, for anxiety, or for
obsessive-compulsive behavior that is often claimed for them. Rather,
as critics point out, psychiatric drugs manifestly interfere with a normal
biological function, to wit, normal neuroreceptor functioning, and take
119. Id. (citing UNITED STATES CONGRESS, OFFICE OF TECHNOLOGY
ASSESSMENT, THE BIOLOGY OF MENTAL DISORDERS (1992))
120. BREGGIN & COHEN, supra note 48.
121. Id. at 35.
122. Id. at 33-34.
123. Id. at 97-98.
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away from mental capabilities a patient would have in the absence of
the drug.
Ross and Pam also claim that psychiatry is related to oppression:
"Biological psychiatry redefines social deviance as a medical problem.
By doing so, it transforms social norms, which are subjective and
political, into medical norms, presumed to be objective and scientific..
Medicalization of social deviance allows us a pretense of
humanitarianism" for coercive measures against people whose
behavior "deviates from expectations based on the dominant social
class's ideology and viewpoint., 12 4  The authors go on to say,
"Psychiatry redefines a great deal of normal human behavior as
medically deviant by pathologizing people who are socially marginal in
any way.' 2 15  Peter Breggin, M.D., claims, "When mental health
professionals point to spurious genetic and biochemical causes" of
depression, and prescribe drugs rather than fostering more authentic
cures, "they encourage psychological helplessness and discourage
personal and social growth" of the type that is crucial to lead a happy
and meaningful life. 26 Dr. Breggin adds this:
Nothing has harmed the quality of individual life in modern
society more than the misbegotten belief that human suffering is
driven by biological and genetic causes and can be rectified by
taking drugs or undergoing electroshock therapy.... If I wanted
to ruin someone's life, I would convince the person that
biological psychiatry is right - that relationships mean nothing,
that choice is impossible, and that the mechanics of a broken
brain reign over our emotions and conduct. If I wanted to
impair an individual's capacity to create empathetic, loving
relationships, I would prescribe psychiatric drugs, all of which
blunt our highest psychological and spiritual functions.
127
The unanimous bias of the pharmaceutical industry is that emotional
states are assimilated into brain states; that is, the former are reducible
124. Ross & PAM, supra note 112, at 22. An example of this pertains to
homosexuals, who, prior to 1974, were deemed socially marginal people when
homosexuality was defined by the American Psychiatric Association as a mental
disorder. Another example occurred in the Soviet Union, where political
dissidents were famously relegated to mental hospitals and treated as
schizophrenics because they opposed Communism.
125. Id. at 228.
126. Peter Breggin, M.D., Another View: Talking Back to Prozac, PSYCHOLOGY
TODAY, July/Aug. 1994, at 72.
127. Peter R. Breggin, M.D., Forward to WILLIAM GLASSER, REALITY
THERAPY IN ACTION xi (2000) (emphasis added).
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to or dependent on the latter. Even if there were some truth to the
idea that some biological condition is associated with depression, the
question remains whether this is a cause or an effect of the depression.
One brain-scan study found that simply asking normal people to
imagine or recall a situation that would make them feel sad resulted in
significant changes in blood flow to the brain."" In other words,
research suggests that emotions cause biological changes in the brain
rather than the other way around.
One of the reasons I think the biological cause of depression is so
popular is that there are times when people are depressed for reasons
that are not at all apparent. That is precisely what Freud suggested in
his elucidation of the unconscious mind. Freud compared the mind to
an iceberg, largely submerged and invisible, and claimed that the
greater part of the mind is irrational and unconscious, and that this
part is "more important in guiding our lives than the rational part,
even though we deceive ourselves into believing it is the other way
around."'29 Moreover, Freud did not believe it was possible to reduce
human emotions to chemical or physiological causes. If people are
given an enhanced sense of well-being through drugs, they will not be
motivated to explore and tackle the source of their previous
discontent. By promoting a distorted view of reality, Prozac in a real
way distances people from reality. If a large segment of society is on
Prozac or similar drugs, the very notion of "reality" will take on a
different, surrealistic, aura.
Many scientists criticize the very notion of "normality," and whether
and how the psychiatric community can scientifically categorize
various symptoms as constituting mental illness. In the book, Myths of
Madness, Don D. Jackson, M.D. says:
On that day when it is generally recognized that "normality" is a
myth, that mankind does not divide into sane and insane, that
mental disorder is not an intractable unalterable ogre unrelated
to ordinary human nature, we will look with more optimism
toward the future. We will recognize that man is fantastically
adaptable (especially when he is given adequate opportunities)
and that most people contribute something to the world. We
128. ANDREASEN, supra note 118 (citing Jose V. Pardo, M.D., Ph.D. et al.,
Neural Correlates of Self-Induced Dysphoria, AM. J. PSYCHIATRY 713 (May 1993)).
129. See id. (citing ALICE KAHN LADAS ET AL., THE G SPOT AND OTHER
RECENT DISCOVERIES ABOUT HUMAN SEXUALITY 6-7 (1982).
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will know that men and women, strangers or neighbors, are not
"less normal" or "more inferior" than we are - just different.
30
VI. THE CONTROVERSY OVER WHETHER SSRIs ENTAIL
SIDE EFFECTS THAT PRECIPITATE SUICIDE
In the early 1990s Eli Lilly faced over 200 lawsuits from people
claiming that Prozac made them harm themselves or others.13' The
number of lawsuits has increased, with claims that the drug
manufacturer knew for years that the drug poses an unreasonable risk
of violent, homicidal, and suicidal behavior for a small but significant
percentage of patients, but that it failed to conduct appropriate tests to
generate the necessary scientific data regarding this linkage and has
failed to warn of these dangers and/or to institute measures in order to
ameliorate the risk.13 Initially, the only acknowledged side effects
stated by Lilly included "anxiety, diarrhea, drowsiness, headaches,
increased sweating, and nausea.' ' 133 Lilly revised its Prozac literature in
May of 1990 to inform physicians of the purported association of
suicidal ideation and Prozac, while denying that there is such an
association in fact.' 4 Litigants have claimed that Lilly knew that there
were at least one or two ways that the design of the chemical
fluoxetine, the drug's chief ingredient, "could have been modified to
make [Prozac a safer drug], but that it chose not to pursue such
reasonable alternative designs."'35
Until recently, the majority consensus of the scientific community
was that there appeared to be "no definitive findings that Prozac
results in the development of suicidal ideation or violence in those
taking the drug." '136 However, the suicide cases subject to litigation
have a unique signature or profile, somewhat distinctive from that of
130. DON D. JACKSON, M.D., MYTHS OF MADNESS: NEW FACTS FOR OLD
FALLACIES 169 (1964).
131. See, e.g., Cole Complaint, supra note 31, 22 (citing "Privilege and
Redaction Log" in the case of Forsyth v. Eli Lilly, Civil CVOO-00401 (D. Haw.
filed), available at http://www.justiceseekers.com/files/NLPP00000/060.PDF.
132. Id.
133. Tomatz, supra note 10, at 707.
134. See Anastasia Toufexis, Warnings About a Miracle Drug: Reports of
Suicide Attempts in Prozac Users Raise Doubts About the Popular Antidepressant,
TIME, July 30, 1990, at 54.
135. Cole Complaint, supra note 31, 2.
136. Vale, supra note 28, at 527.
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the suicidality otherwise noted in depressed patients. The
phenomenon has four distinctive attributes:
(a) either de novo thinking about suicide or, an incremental or
quantum increase in the severity of a patient's suicidality (like a
progression from "passive" thoughts of suicide to an "active"
suicidal plan or attempt);
(b) an "obsessional" quality where the ideas about suicide "seem
to intrude" into the person's mind;
(c) the thoughts, attempt or suicidal act were of a violent nature;
and
(d) then, finally, the most difficult term to describe is that they
were egodystonic--they were egodystonic and/or discord. [sic]
They were not wanted --did not seem to fit with the rest of the
ways that the individual patients were thinking, certainly not
something they were truly planning to do .... Foreign to the
person and also not a true intent of the person."'
The first postulation of suicidal ideation associated with Prozac was
reported by Dr. Martin H. Teicher et al., who noted that six depressed
patients who never before had suicidal ideation, developed intense and
violent suicidal preoccupation at a mean of twenty-six days after
treatment with Prozac commenced.1 8 There was no evidence
that strong preexisting self-destructive urges were activated and
energized by fluoxetine. No patient was actively suicidal at the
time fluoxetine treatment began. Rather, all were hopeful and
optimistic, and the strong obsessive suicidal thoughts emerged
de novo after weeks or months of treatment. In four patients...
, these thoughts were accompanied by abject acceptance and
detachment. Two patients . . . tried to conceal their suicidal
feelings and impulses and to continue fluoxetine treatment,
believing that the drug would eventually enable them to
successfully kill themselves!...
Dr. Teicher also was amazed at how violent the patients' suicidal
ideations were:
Two patients fantasized, for the first time, about killing
themselves with a gun .... and one patient ... actually placed a
loaded gun to her head. One patient.., needed to be physically
restrained to prevent self-mutilation .... [Another patient], who
137. Cole Complaint, supra note 31, at T 9.
138. Martin H. Teicher et al., Emergence of Intense Suicidal Preoccupation
During Fluoxetine Treatment, 147 AM. J. PSYCHIATRY 2, 207, 209 (1990).
139. Id. at 209.
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had no prior suicidal thoughts, fantasized about killing himself in
a gas explosion or a car crash) 40
The Teicher study was criticized in subsequent publications.
41
Skeptics generally argued that for findings to be conclusive on the
question of suicidal ideation, a double-blind, randomized trial design
would be necessary. 42 At the same time, others have opined that the
frequent development of akathisia reported in patients taking Prozac
and other antidepressants could be implicated as the specific cause of
new-onset suicidal ideation and violence.14  And at present, over a
decade after the Teicher study, there are numerous scientific studies
and anecdotal reports that lend credence to the theory that Prozac and
other SSRIs cause suicidal ideation and homicidal behavior'
44
During the first testing of fluoxetine hydrochloride on animals in
1977, Lilly's scientists discovered that the drug suppressed deep sleep
and hence suppressed rapid eye movement (REM) in the subject
animals. But more alarmingly, Lilly's scientists wrote:
By the fourth day of drug treatment the cats receiving the larger
doses, which had been friendly for years, began to growl and
hiss.... After cessation of the drug treatment, the cats returned
to their usual friendly behavior in a week or two; those on the
higher doses recovering more slowly.
145
Similar aggressive behavior was noted in dogs receiving high doses)
46
In 1986, the German government rejected Lilly's application to
market Prozac there, in part because of its evaluation of evidence that
suggested the drug posed an increased risk of suicide in those who
140. Id.
141. See Vale, supra note 28, at 534.
142. Id. (citing Charles M. Beasley, Fluoxetine and Suicide: A Meta-Analysis of
Controlled Trials of Treatment for Depression, 303 BRIT. MED. J. 685 (1990)).
143. Vale, supra note 28, at 535 (citing R.A. King et al., Emergence of Self-
Destructive Phenomena in Children and Adolescents During Fluoxetine Treatment,
30 J. AM. ACAD. CHILD & ADOLESCENT PSYCHIATRY 179 (1991)); William C.
Wirshing, Fluoxetine, Akathisia, and Suicidality: Is There a Causal Connection?, 49
ARCHIVES GEN. PSYCHIATRY 580 (1992).
144. See Eric W. Fine, M.D., Selective Serotonin Reuptake Inhibitors (SSRIs)
and Cases of Alleged Related Violence, 23 AM. J. FORENSIC PSYCHIATRY 5 (2002)
(concluding that cases involving Prozac-induced suicide and homicide cannot be
ignored and that each individual case requires careful and comprehensive
evaluation on its merits).
145. Cole Complaint, supra note 31, 15.
146. Id.
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otherwise had no suicidal tendencies.14 The question of whether
Prozac causes suicide ideation came to public attention in the United
States in a February 1990 article entitled "Emergence of Intense
Suicidal Preoccupation During Fluoxetine Treatment," by Harvard
psychiatrists Martin Teicher, Jonathan Cole and Nurse Carol Glod1
48
According to critics of Prozac, Eli Lilly, in its zeal to produce a
blockbuster drug, manipulated results of clinical trials by controlling
the design of the studies and making public only positive data. For
example, it has been documented that in the clinical trials,
approximately 5.3% of patients dropped out because of side effects
involving akathisia (a turmoil or state of agitation which, when drug
induced, is accompanied with panic and an awareness of strange and
unusual impulses that the affected individual does not ordinarily
have) 149 or an incipient serotonin syndrome. In other words, the group
of patients who experienced the most serious side effects dropped out
of the trials and as a result their side effects were not reported in the
study.5 The FDA noted in a Memorandum dated November 13, 1994,
"This Agency must inform Lilly early on that we have problems with
their analysis because of the large number of dropouts."'' Moreover,
Lilly allowed clinicians conducting the trials to administer sedatives to
other patients to mask side effects pertaining to violence or suicide
ideation. 52 An FDA epidemiologist, Dr. David Graham, stated that
"the firm's analysis of suicidality does not resolve the issue," and that
"because of apparent large scale under reporting, the firm's analysis
cannot be considered as proving that fluoxetine and violent behavior
are unrelated.'
53
Many believe that the FDA did not receive a full picture of the
available research in 1991 when the FDA examined the question of
suicide ideation associated with Prozac. FDA procedures required
Lilly to inform the agency of any concerns about Prozac raised by
other national health authorities, but Lilly never told the FDA or the
147. Id. at T 11.
148. See Martin Teicher, Jonathan Cole & Carol Glod, Emergence of Intense
Suicidal Preoccupation During Fluoxetine Treatment, 147 AM. J. PSYCHIATRY 2
(1990).
149. See Robert Lane, SSRI-Induced Extraphramidal Side-effects and Akathisia:
Implications for Treatment, 12 J. OF PSYCHOPHARMACOLOGY 2 (1998).
150. See Blowers Complaint, supra note 26, at j 9.
151. Id .at 28. Under the FDA's own analysis of its statistical system, there
have been approximately 20,000 Prozac related suicides since 1987. Id. at T 30.
152. See id. at 28.
153. Id.
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expert panel that German regulators initially refused to approve
Prozac's sale in 1986 because of concerns over a link with suicide.
15 4
German authorities had noted that Prozac seemed to have caused a
substantial increase in suicide among patients using the drug.
15
1
Eventually, the drug was approved in Germany with a warning that
physicians should consider using sedatives for patients at risk of
suicide.56 In the United States, no such warning is included in Prozac's
literature, although the risk of suicidal ideation is listed among the
drug's side effects. 57
How SSRIs contribute to suicide ideation is not entirely clear, but
some researchers suggest that one possibility is that the drugs produce
restlessness, impulsiveness, agitation, or manic episodes - akathisia - in
many patients that could lead to self-destructive behavior.
The questions regarding the safety of Paxil, Prozac, and Zoloft
continue to be disturbing. In June 2003, British drug authorities
reported that unpublished studies about Paxil show that it carries
substantial risk of suicide ideation in teenagers and children.'58 The
report said that nine studies of Paxil revealed 3.2 times the likelihood
of suicidal thoughts or suicide attempts among teens and children
given the drug compared to patients given a placebo. 9 This concern
was echoed a week later by the Food and Drug Administration.'6 In
addition, the studies found that Paxil was no more effective than a
placebo in treating depression in youngsters. Since all the SSRIs act
similarly in the body, these concerns about Paxil extend to the other
antidepressant drugs.'
6 '
154. Gardiner Harris, Debate Resume on the Safety Of Depression's Wonder






Even in adults, SSRIs have been found to offer only modest benefits. In about
one-half of all adult tests, the drugs prove no more effective than placebos. ...
According to a survey in 2000 of studies used by the F.D.A. in approving the drugs,
... on average, they reduce symptoms of depression by about 41 percent on a






The threat of suicide in patients who take SSRIs was weighed and
rejected by regulators in past years. The latest findings give fresh
urgency to claims of plaintiffs' lawyers who assert that drug makers
withheld evidence of the SSRIs' suicide risk from regulators.162 Of the
ten American members of an ad hoc FDA panel that had cleared the
drugs from being a suicide risk in 1991, seven now say that the new
information would prompt them to reconsider that decision.'63 One of
the members, Dr. Jeffrey A. Lieberman, said, "In 1991, we said there
wasn't sufficient evidence to support a link between these drugs and
suicide. Now there is evidence, at least in children, and I wouldn't rule
out that it's in adults, too."' 6
At the time of publication of this article, the FDA announced it was
convening a panel to meet in February 2004 to re-examine the
relationship between suicide and SSRIs.'65 The panel will consider
whether the drugs should be prescribed to teenagers and children,
whether warnings accompanying the drugs should be changed, and
what studies should be conducted to determine if there really is a link
between suicide in youngsters and the use of SSRIs. 66 In preparation
for the meeting, the FDA is reviewing pediatric studies. Studies of
Paxil showed that children taking the drug were more likely to attempt
suicide than those taking placebos, and that Paxil did not improve
symptoms of depression in the subjects who were studied.
16 1
According to Dr. Graham Emslie, professor of psychiatry at the
University of Texas Southwestern Medical Center, who was a
researcher in four of GlaxoSmithKline's studies of Paxil, some
companies have withheld negative findings pertaining to SSRIs: "I
know of at least a half-dozen other studies of antidepressant
treatments in children and adolescents that have been completed but
as yet have not been published. More than enough time has passed for
these to be published at least in abstract form."' '
It might be conceded that there is an inherent difficulty in
pinpointing the cause of suicide committed by seriously depressed
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commit suicide, and at the same time millions of depressed
individuals take Prozac every year. Although many risk factors for
suicidality are well known, there is no clinical test, technique, or
biological marker sufficiently trustworthy to support an accurate short-
term prediction of suicide in individual patients.170  Thus, it is a
daunting challenge to determine whether certain depressed people
take their lives as a result of taking Prozac or other SSRIs, rather than
as a result of their disease. Frederick K. Goodwin, a government
psychiatrist who specializes in depression, says, "It wouldn't be
surprising over time to see thousands of suicides among more than
three million depressive patients.' 71 In addition, many people taking
SSRIs have suffered years of mental disturbances and even severe
depression, making it difficult to attribute specific cases of suicidal
ideation to the drug itself. Untreated depression results in a higher
risk of suicide, so refusing treatment with Prozac because of its
negative portrayal could ironically result in a higher risk of suicide,
thereby exacerbating the very risk that the patient is trying to avoid.
On the other hand, in situations where suicidal ideation is a de novo
symptom, particularly where this is temporally close in time to the
onset of taking an antidepressant, there could be strong circumstantial
evidence of causation. Further, given the wealth of published
epidemiological data in scientific journals asserting a connection
between Prozac and suicidal ideation, as discussed above, expert
testimony supporting causation may likely be submitted to a jury.
There appears to be ample reason for physicians to be mindful of the
strands of evidence, both anecdotal and scientific, outlined above, and
to be particularly vigilant in prescribing antidepressants to patients
who may have a pre-existing tendency towards suicidal ideation.
VII. THE STATUS OF THE "PROZAC DEFENSE" IN CRIMINAL
LAW
The so-called "Prozac defense" in criminal cases, once ridiculed,
actually is becoming a legally cognizable defense. The theory behind
the defense is that the drug causes involuntary conduct as a side effect,
and that the drug in fact caused a given defendant to kill or commit
169. See Tracy Schroth, Defending Prozac: Divide, Discover, and Conquer,
LEGAL TIMES, Dec. 16, 1991, 2, 13.
170. See Fine, supra note 144, at 7.
171. Thomas M. Burton, Anti-Depression Drugs of Eli Lilly Loses Sales After
Attack By Sect, WALL ST. J., Apr. 19, 1991, at Al.
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some other crime at issue.' Proponents of the "Prozac defense" argue
that during an SSRI-induced mania a person can make elaborate plans,
including robberies and other crimes, and that sometimes the mania is
exacerbated by psychotic features such as hallucinations or delusions.
73
"Drug-induced mania can cause many expressions of disinhibited or
out-of-control behavior, including sexual acting out, road rage, buying
sprees and shoplifting. Drug-induced mania, even when seemingly not
intense, can ruin marriages and destroy careers.'
'174
The "Prozac defense" relies on the doctrine of involuntary
intoxication. Generally, the defense of involuntary intoxication is a
complete defense in jurisdictions that have adopted the M'Naghten
definition of insanity.'75 The general view is that intoxication resulting
from medication that "has been prescribed (and taken as prescribed)
or administered by a physician, is involuntary intoxication.' ' 76 As early
as 1915 the idea of involuntary intoxication due to drugs entered into
jurisprudence in the case of Perkins v. United States,'7 where a Federal
appellate court said:
A patient is not presumed to know that a physician's
prescription may produce a dangerous frenzy. . . . If [the
defendant] was so frenzied by a portion of the medicine
innocently taken under the direction of the physician that he was
thrown into a mental state which placed him beyond his own
control and beyond the realization of what might be the ill effect
of an overdose, he would not be legally responsible.
The notion of involuntary intoxication takes into account that
patients have no duty to discover that a drug is defective or
unreasonably dangerous, nor to guard against its existence. 78 Certain
products are regarded as unavoidably unsafe products. That is, they
are products that "are quite incapable of being made safe for their
intended and ordinary use." '79 If Prozac is in fact an unavoidably
172. See Garza v. State, 829 S.W.2d 291 (Tex. App. 1992) (ruling that the trial
court did not err in overruling the defendant's requested instruction of involuntary
intoxication because the defendant had not raised the defense at trial).
173. See Paxil Withdrawal Suit Resolved, supra note 63.
174. Id.
175. WAYNE R. LAFAVE & AUSTIN W. SCOTr, CRIMINAL LAWS § 4.10(f), at
393-94 (2d ed. 1986).
176. Phillip E. Hassman, Annotation, When Intoxication Deemed Involuntary so
as to Constitute a Defense to Criminal Charge, 73 A.L.R.3d 195, §7(a) (1977).
177. Perkins v. United States, 228 F. 408,415-16 (4h Cir. 1915).
178. RESTATEMENT (SECOND) OF TORTS, §402A cmt. n (1965).
179. RESTATEMENT (SECOND) OF TORTS, §402A cmt. k (1965).
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unsafe product, the manufacturer would need to provide an adequate
warning to physicians and patients that its use may cause destructive,
suicidal, or homicidal urges in some of its users.' 8° According to
comment "j" of Section 402A of the Restatement (Second) of Torts, if
the seller knows or "by the application of reasonable, developed
human skill and foresight should have knowledge" of a danger, then
the seller must warn against it.'8 ' Furthermore, "a product sold without
such a warning is in a defective condition."'8  This provision is
interpreted to mean that a drug manufacturer is held to be an expert in
its own field and presumed to keep abreast of scientific data pertaining
183to its product. In addition, "if a substantial number of doctors or
consumers had complained to a drug manufacturer of an untoward
effect of a drug, that would have constituted sufficient information
requiring an appropriate warning" by the company.184
Under this legal backdrop, to what extent has Eli Lilly been
provided notice about the possible dangers of using Prozac? Mounting
scientific and anecdotal evidence, plus individual reports and general
post-marketing monitoring, suggest that the manufacturer should by
now be apprised of a risk that (to put it in the most charitable light) it
may not have known existed at the time the drug was manufactured.
This information would appear to support the need of a suicidal
ideation warning.
After the Wesbecker rampage in Louisville, in which a man with a
history of depression who was taking Prozac shot and killed co-
workers and himself (see discussion below), Eli Lilly began to mention
the episode in its May 1991 package insert, but the company failed to
provide a general warning about suicidal and homicidal tendencies.'
8
The company's refusal to provide a more concrete warning is
consistent with its overall position that there is no causal connection
between Prozac and self-destructive behavior. Still, there is authority
for the proposition that "under a strict liability theory, a manufacturer
must warn of dangers and risks, whether or not a causal relationship
between use of the product and various injuries has been definitively
established at the time of the waring.186  Under this rule, a
180. See Tomatz, supra note 10, at 717.
181. RESTATEMENT (SECOND) OF TORTS, §402A cmt. j (1965).
182. RESTATEMENT (SECOND) OF TORTS, §402A cmt. h (1965).
183. Tomatz, supra note 10, at 718.
184. Feldman v. Lederle Lab., 479 A.2d 374, 387 (N.J. 1984).
185. Tomatz, supra note 10, at 719.
186. Hamilton v. Hardy, 549 P.2d 1099, 1108 (Colo. Ct. App. 1976). See also
Feldman, 479 A.2d at 389 (citing Hamilton with approval).
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manufacturer cannot interpose the defense that it did not warn
because causation had not been conclusively established between a
drug and the onset of suicidal ideation or homicidal tendencies.
Moreover, drug manufacturers must warn of dangers even where the
deleterious effect occurs in only a handful of "idiosyncratic or
hypersensitive users."' 7
As mentioned above, Lilly does provide certain warnings. The
company notes, for example, that the drug is eliminated relatively
slowly so that its active ingredients can accumulate in the body. "The
long elimination half-lives of fluoxetine ... assure[s] that, even when
dosing is stopped, active drug substance will persist in the body for
weeks (primarily depending on individual patient characteristics,
previous dosing regimen, and length of previous therapy at
discontinuation). '"'8 Some of the warnings given by the company are
in fact nothing more than direct quotes from the Physician's Desk
Reference (PDR). For example, the only mention of suicide ideation is
this: "The possibility of a suicide attempt is inherent in depression and
may persist until significant remission occurs. Close supervision of
high risk patients should accompany initial drug therapy."1 89 In fact,
this statement is lifted directly from the Physician's Desk Reference
(PDR).'9°  The company's warnings also has a section entitled
"Interference With Cognitive and Motor Performance," in which it
states, "Any psychoactive drug may impair judgment, thinking, or
motor skills, and patients should be cautioned about operating
hazardous machinery, including automobiles, until they are reasonably
certain that the drug treatment does not affect them adversely."' 91 This
is nothing more than a general advisory somewhat similar to that
found on over-the-counter night time cold remedies. The company
also discloses adverse events including anxiety, nervousness, tremor,
nausea, dry mouth, and decrease of libido reported by a significant
number of patients.'2
Lilly probably does not want to provide a more detailed warning
because it could frighten consumers. However, comment "k" of the
Restatement (Second) of Torts sets forth what is known as the risk
187. Basko v. Sterling Drug, Inc., 416 F.2d 417,430 (2d Cir. 1969).
188. PROZAC DESCRIPTION, supra note 27.
189. Id. at 9.
190. See MEDICAL ECONOMICS DATA, PHYSICIANS' DESK REFERENCE 921
(1992).
191. PROZAC DESCRIPTION, supra note 27, at 10.
192. Id. at 15, Tbl. 1.
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utility doctrine, and provides an example of a safe haven for useful
products that involve risk:
An outstanding example is the vaccine for the Pasteur treatment
of rabies, which not uncommonly leads to very serious and
damaging consequences when it is injected. Since the disease
itself invariably leads to a dreadful death, both marketing and
the use of the vaccine are fully justified, notwithstanding the
unavoidable high degree of risk which they involve. Such a
product, properly prepared, and accompanied by proper
directions and warning, is not defective, nor is it unreasonably
dangerous.1 93
Under this risk utility doctrine Eli Lilly could provide a more
detailed warning and thereby be exempted from strict liability,
assuming that Prozac's usefulness outweighs the known risks. That is,
the risk utility analysis strives to balance the apparent benefits of a
drug with the known risks as set out in the warning information.
The fact that the FDA has approved the language on a warning label
is "not necessarily conclusive on the question of the adequacy of the
warnings."' 94 Manufacturers have a duty to monitor information about
their products, and FDA warnings are considered adequate only if the
manufacturer is not privy to information pointing to a greater
danger. 95  Interestingly, the FDA reviewed escalating reports of
suicidal ideation, and its Psychopharmacologic Advisory Committee
released its report in September 1991. The ten-member committee
"unanimously declined to recommend any change in warning or
prescription practice on Prozac."' 96 The committee found "no credible
evidence" supporting the reports that there was a causal connection
between Prozac and suicidal or violent behavior in its users.'9 This
must have fueled Lilly's consistent position that there is no connection
between Prozac and self-destructive or violent behavior, so that there
is nothing to warn about.9
193. RESTATEMENT (SECOND) OF TORTS, § 402A cmt. k (1965).
194. Brochu v. Ortho Pharmaceutical Corporation, 642 F.2d 652, 658 (1' Cir.
1981) (quoting Chambers v. G.D. Searle & Co., 630 F. Supp. 1087, 1095 (D. Md.
1986)).
195. Id.
196. Charles Petit, Tough Times for an Anti-Depressant, S.F. CHRON., Sept. 25,
1991, at Al.
197. Schroth, supra note 169, at 14.
198. ELY LILLY & CO., 1991 SECOND-QUARTER REPORT 6 (1991) (company
argues that negative thoughts occur as a concomitant to depression, and since
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Recently, the defense of involuntary intoxication in connection with
prescription drugs gained credibility in Minneapolis v. Altimus,"'9
where the defendant claimed that by taking Valium he was
unexpectedly intoxicated. The Minnesota Supreme Court established
three criteria for interposing a successful defense of involuntary
intoxication caused by ingestion of a prescription drug: (1) "the
defendant must not know, or not have reason to know, that the
prescribed drug is likely to have an intoxicating effect"; (2) "the
prescribed drug, and not some other intoxicant, is in fact the cause of
the defendant's intoxication at the time of the alleged criminal" act;
and (3) "the defendant, due to involuntary intoxication, must be
temporarily insane."2°°
Some courts have in fact accepted the involuntary intoxication
defense in connection with Prozac or other SSRIs, apparently
following the three-prong criteria just mentioned. In effect the courts
are finding that the involuntary use of the drug or drugs created a state
of mind equivalent to insanity or temporary insanity. In Connecticut a
judge acquitted a defendant, Christopher DeAngelo, of first-degree
robbery based on the finding that the defendant was unable to
appreciate the wrongfulness of his conduct or to control his conduct
within the requirements of law, and that this impaired state was
specifically attributable to his taking Prozac and Xanax.20' The
defendant had committed several robberies over the course of a few
days, including the bank where his wife worked, and was easily
recognized in the course of these episodes because of a vintage car he
drove.202 The defendant had no prior history of any criminal or
aggressive behavior; he had no financial problems, and was considered
a very responsible person by co-workers, family, and friends. The
judge in that case relied on a forensic psychiatrist's report stating that
the defendant experienced disinhibition (i.e., paradoxical behavior)
and mania induced by the Prozac and Xanax. The report said, "Both
syndromes are characterized by lack of self-control, judgment, and
insight," that both "can cause or include out-of-character, irrational,
senseless, impulsive, bizarre and destructive behavior," and "they can
produce criminal actions that make no sense in terms of the
Prozac users often suffer from depression in the first instance, it is the depression
and not the drug that causes destructive urges).
199. Minneapolis v. Altimus, 238 N.W.2d 851,854 (Minn. 1976).
200. Id. at 857.
201. See COURT FINDS PROZAC AND XANAX CAUSE CRIMINAL CONDUCr,
available at http://www.breggin.com/deangelo.html (last visited Feb. 8, 2004).
202. Fine, supra note 144, at 27.
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individual's self-interest, and which are bound to be discovered.,
20 3
The psychiatric report concluded that if the defendant had not been




In another Prozac defense case a Georgia man accused of robbery
was diagnosed with a Prozac and Xanax induced Mood Disorder with
Manic Features, and the prosecution agreed to a plea bargain as a
result of a forensic psychiatrist's report, dropping nine counts of
robbery and four counts of kidnapping.0 5 In another case, a Virginia
man, charged with assault against the police, was acquitted on grounds
of involuntary intoxication with psychiatric drugs, based on forensic
psychiatric testimony2
In 1999 an Australian court ruled that the defense of diminished
responsibility applied to David John Hawkins, who has confessed to
strangling his wife of fifty years despite the loving relationship that had
existed between them even at the time of the homicide. The judge in
201the case Regina v. David John Hawkins opined that the defendant
was under the influence of a prescription for Zoloft, which he had
started taking only one day before the homicide. The defendant pled
guilty to the reduced charge of manslaughter on the grounds of• '- 208
diminished responsibility. The defendant had no prior history of
violence. The judge, relying on statistics from the Australian
Department of Health and Aged Care, as well as forensics reports,
stated in his opinion:
The effective drug in Zoloft is capable of causing sleeplessness,
agitation, confusion, hallucination and psychosis. Furthermore,
because responses to antidepressants can be idiosyncratic the
effect of a given dose on one particular individual may be more





205. See Paxil Withdrawal Suit Resolved, supra note 63.
206. CENTER FOR THE STUDY OF PSYCHIATRY AND PSYCHOLOGY, ASSAULT
CHARGES DISMISSED ON GROUNDS OF INVOLUNTARY INTOXICATION WITH
PSYCHIATRIC DRUGS, at http://www.breggin.com/invintoxication.html (last visited
Feb. 8, 2004).
207. Regina v. Hawkins (2001) N.S.W.S. Ct. Cas. 420, available at http://www.
justiceseekers.com /files/NLPPOOOOO/052.PDF.
208. Fine, supra note 144, at 26.
209. Regina v. Hawkins (2001) N.S.W.S. Ct. Cas. 420, 34.
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...Zoloft can cause agitation and a certain amount of
disinhibition so that some individuals engage in aggressive or
dangerous behaviours without due regard for the consequences
and in a manner that is out of character for them. Behaviour of
such a kind is sometimes described in terms "that suggest manic
or psychotic reactions". Zoloft can also lead to suicide. In this
regard it should be noted that when medically examined shortl0y
after his arrest the prisoner was found to be "acutely suicidal".2 '
The manifestations of aggression, agitation, confusion and
hallucination experienced by the prisoner are thus readily able
to be explained by reference to the Zoloft which he had ingested
in the early hours of 1 August, 1999."'
The judge quoted from portions of the forensics reports, including
the following:
The unusual factor in my opinion was the fact that [the prisoner]
was taking Zoloft at the time and this produced a strange and
unusual state of mind in him involving akathisia and possibly
also emotional blunting and psychotic decompensation and this
led directly to his behaviour on ...August 1st 1999. In my
opinion had he not been taking Zoloft the events of that night
would not have happened. The temporal association between
his intake of Zoloft and these events and the congruence of this
time frame with the time frame reported in the literature argue
strongly for an SSRI (Selective Serotonin Re-uptake Inhibitor)
212induced problem.
One forensic expert stated that SSRIs can cause one in four healthy
volunteers to exhibit moderate to severe agitation, which "could lead
to violent behavior.,
213
The judge nevertheless sentenced the defendant to three years in
prison with a non-parole period of two years, meaning that he would
be in prison for only a short time. The judge imposed some prison
time because the defendant had previously taken Zoloft and then
stopped because he had been aware that it had an adverse effect on
him; the dose taken by him at the time of the homicide was several
times in excess of what had been prescribed; and while his
214
responsibility was diminished, it was not entirely eliminated .
210. Id. at 38.
211. Id. at 39.
212. Id. at 43.
213. Fine, supra note 144, at 26.
214. Regina v. Hawkins (2001) N.S.W.S. Ct. Cas. 420, 72.
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In a federal civil suit based on product liability, a Wyoming jury
found that Paxil caused Donald Schell to shoot and kill his wife,
daughter, and granddaughter, as well as commit suicide, and awarded
eight million dollars in damages to his heirs, saying that Paxil "can
cause some individuals to commit suicide and/or homicide.""21 Schell
took one tablet of Paxil daily for just two days before the fatal incident.
The question before the jury was whether taking one tablet of Paxil
daily for two days caused Donald Schell to commit murder and suicide,
or whether the extreme aggression and violence was caused by his
clinical depression. The jury deliberated for five hours and found the
defendant eighty percent liable and Donald Schell twenty percent
liable.216 The plaintiffs' attorney made the argument that the jury
should consider a broader question, namely, whether it is possible that
the drug produces a violent reaction in some people.1 7 The case
focused on allegations that SmithKline never fully tested the
propensity of Paxil to cause violence or suicide, and that they took
affirmative steps to mislead the public and the medical profession
about this problem."8 Schell had a past history of five previous bouts
of depression that were severe enough to keep him from work, and he
had sporadic psychiatric treatment." 9 He had a history of taking other
antidepressants, including Prozac.2 °
This case set a legal precedent in that it was the first time a jury
found a pharmaceutical firm liable for a death caused by a patient
taking an antidepressant. 22  The case implies that other SSRI
antidepressants could be implicated by association. Part of the
discovery in the case revealed that GlaxcoSmithKline was "aware that
a small number of individuals had become agitated or violent while
taking Paxil.
' 222
215. Tobin v. SmithKline Beecham Pharmaceuticals, No. 00-CV-0025-Bea (D.
Wyo. Filed May 8, 2001), available at http://www.justiceseekers.com/files/NLPPOO
000/042.PDF. See also Fine, supra note 144, at 22-23.
216. Fine, supra note 144, at 24.
217. Id. at 23.
218. See id. at 24.
219. See id.
220. See id.
221. Id. at 22.
222. Fine, supra note 144, at 23. GlaxcoSmithKline's clinical trial of 2000
healthy volunteers who were given either Paxil or a placebo showed that
[m]any of the subjects developed adverse reactions, ranging in severity
from mild anxiety to, in a very small number, suicidal ideation. Some of
them experienced anxiety, nightmares, hallucinations and other side-
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The jury's verdict suggests that "a warning about possible suicide,
violence or aggression should have been included in the warning
insert" for Paxil. 23 "None of the manufacturers of SSRIs have issued
such a warning. ,224 According to one attorney familiar with the
ongoing litigation with respect to SSRIs, Pfizer, which manufacturers
Zoloft, and Eli Lilly had internal documents indicating they had
knowledge of these side effects.2z
Some people question whether the internal documents of
GlaxcoSmithKline are scientifically helpful in ascertaining the effects
of antidepressants on patients who have clinically significant major
depressive disorder, since the subjects who participated in the study
were healthy volunteers and did not receive
the kinds of comprehensive psychiatric evaluations that inquire,
at a meaningful level, about past histories of violent behavior or
past psychosocial stressors and their impact on their coping
mechanism. . . . Drawing conclusions from the effects of
antidepressant medications on healthy volunteers ... does not
seem a very scientifically accurate way to draw conclusions that
226these drugs cause aggressive or violent behavior.
However, the judge in the Schell case, U.S. Magistrate William C.
Beaman, issued a thirty-one page opinion in which he denied the
defendant's motion to exclude or limit plaintiffs' experts' testimony.
One of plaintiffs' experts, John T. Maltsburger, said this in his report:
It is generally understood by most psychiatrists that a certain
number of patients, perhaps five percent, will develop
restlessness and anxiety when prescribed selective serotonin
uptake inhibitor drugs (SSRIs) of which Paxil is an example....
Furthermore, a certain number of depressed patients are known
to "switch" in to hypomanic states when treated with
antidepressant drugs. When a patient has a hypomanic history..
• or already exhibits akathisic symptoms .... SSRI compounds
should not be prescribed because they have the potential to
make the anxiety much worse, indeed, to make it unbearable.
There are credible reports of patients becoming suicidal and
effects within two days of taking Paxil, and one experienced akathisia
after four days. Two volunteers attempted suicide after 11 and 18 days
respectively.
Id. at 24.
223. Id. at 23.
224. Id. at 24.
225. Id.
226. Id. at 24-25.
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homicidal when thrown into intolerable states of anguish by
prescription of these drugs.... Further, we know that depressed
patients given SSRI drugs are more likely to harm themselves
than are those who are given tricyclic antidepressants ...
Already anxious, his mind speeding, and sleepless, when given
an SSRI in 1998, he [the decedent] quickly became violent and
killed his family and himself .... In this case I can identify only
one factor which triggered the murders and subsequent suicide--
Paxil .... Though we lack details of what exactly Mr. Schell's
mental state was on that fatal night, it is clear to me that it was
Paxil that drove him out of control.2"
Judge Beaman noted that while there are significant differences in
the chemical structures, chemical properties, and ability to inhibit the
reuptake of serotonin of the various SSRIs, SSRIs are often classified
together and collectively referred to as "the SSRIs" by the scientific
and medical communities because of their similar ability to block
serotonin reuptake:
SSRIs are widely referred to in the scientific community as
SSRIs precisely because they share this physiological property
and the functional effects of this property [the inhibition of the
reuptake of serotonin] in common. These drugs in fact share a
wide range of functional effects in common. The list of side-
effects for all of the drugs in the class overlaps heavily.... The
general designation of these drugs as SSRIs . . . refers to a
common understanding that broadly speaking the drugs are
similar - there may be differences but there is broad overlap.2
In 1994 there were approximately 160 active Prozac cases involving
suicide or acts of violence committed by persons who were taking
Prozac. 229 The first Prozac suit in the nation to reach a courtroom was
precipitated in September, 1989, when Joseph Wesbecker, who had
started taking Prozac a month earlier, armed himself with an AK-47
and walked into the Louisville printing plant where he had worked,
227. Id. at 4. The judge also cited "the Donovan study," which provides
significant support for the causations opinions and methodology employed by the
expert witnesses employed by the plaintiffs. Stuart Donovan et al., Deliberate Self-
Harm and Antidepressant Drugs Investigation, 177 BRIT. J. PSYCHIATRY 551, 554
(Dec. 2000).
228. Tobin v. Smith Kline Beecham Pharmaceuticals, No. 00-CV-0025-Bea (D.
Wyo. Filed May 8, 2001), available at http://www.justiceseekers.com/files/NLPPOO
000/042.PDF.
229. Richard Zitin & Carol M. Langford, Hide and Secrets: The depressing tale
of a clandestine Prozac settlement, 156 N.J. L.J., 24-25 (1999).
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killed eight people, wounded twelve more, and committed suicide. °
Survivors of the shooting victims brought a wrongful death and
products liability case known as Fentress v. Eli Lilly,23 and at trial
sought to introduce evidence that Lilly had pled guilty in 1985 to
twenty-five criminal counts for failing to report adverse reactions,
including four deaths, to the FDA in connection with another Lilly
product, an anti-inflammatory drug called Oraflex, which had been
232
taken off the market in 1982 as too dangerous. It was plaintiffs'
intention in the Fentress case to show that Lilly had done the same
thing with Prozac.233 When the judge indicated that he would allow
that evidence to go before the jury, there was a "flurry of activity" in
which counsel for the plaintiffs and counsel for Lilly made a secret
verbal agreement to settle the case; but it was agreed that plaintiffs'
attorney would immediately rest his case without introducing the
damaging Oraflex evidence. The jury returned a verdict in favor of the
defense.234 Lilly's defense attorney said in a press conference:
We have proven in a court of law, just as we have to more than
70 scientific and regulatory bodies all over the world, that Prozac
is safe and effective. Our hearts go out to the victims of the
terrible tragedy .... But the members of the jury, after hearing
the scientific and medical facts . . . came to the only logical
conclusion - that Prozac had nothing to do with Joseph
235Wesbecker's actions.
As revealed later by an investigation by the Kentucky State
Attorney General, Lilly secretly agreed to pay the plaintiffs, win or
236lose. In addition, Lilly agreed that all of the plaintiffs' lead counsel's
other Prozac cases would be settled, and half of his expenses would be
paid by Lilly. 37
In 1998 it was disclosed that about a dozen cases involving Prozac
disappeared from the court record, with the implication that the cases
had been "resolved." 238 "The history of Prozac litigation reads like a
230. Id.
231. Fentress v. Eli Lilly & Co., No. 90-CI-06033 (Cir. Ct., Jefferson County,
Ky. Jan. 25, 1995) (judgment dismissing case with prejudice).
232. Zitin & Langford, supra note 229.
233. Id.
234. Id.




238. Id. at 36.
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mystery thriller, filled with allegations of backroom deals, hidden
agendas, and unethical behavior. Although many of the details have
circulated among trial lawyers, new revelations continue to
percolate." '239
A recent case involves a thirteen-year-old boy, Matthew Miller,
whose parents sued Pfizer claiming he had committed suicide because
he took Zoloft, manufactured by Pfizer, for the treatment of
depression. The case, Mark Miller and Cheryl Miller v. Pfizer Inc.,'
40
held that forensics testimony would be excluded on the issues of (1)
general causation (whether Zoloft causes suicide); (2) specific
causation (whether Zoloft caused Matthew Miller's suicide); and (3)
the adequacy of Pfizer's Zoloft warnings to physicians.2 4 ' The basis of
the court's ruling was that the proffered testimony pertained to
statistical calculations that "did not represent a generally accepted
methodology for testing the hypothesis that Zoloft causes suicide, and
therefore general causation was not established.
2 42
In recent years Eli Lilly has offered to indemnify doctors who
prescribe Prozac and are sued for malpractice arising from prescribing
the drug, in addition to helping prosecutors thwart attempts of
defendants to interpose the "Prozac defense" in criminal cases.24 3
Lilly's indemnification to doctors includes "the cost of defending any
litigation as well as any judgments that should arise from lawsuits
challenging the use of Prozac.",24 By indemnifying physicians, Lilly has
foreclosed the possibility of claiming intervening negligence on the
part of doctors that could exonerate the company from liability,
particularly since the company has given constant assurances about
Prozac's safety to doctors. 24'
239. Id. at 38.
240. See Miller v. Pfizer Inc., No. 99-2326 (D. Kan. Feb. 7, 2002).
241. Id.
242. Id.
243. See Jonathan M. Moses, Lilly Order to Turn Over Prozac Studies, WALL.
ST. J., Jan. 17, 1992, at B1.
244. Daniel Wise, Eli Lilly to Pay Legal Expenses, Awards to Doctors in Prozac
Suits, N.Y. L.J., June 6, 1991, at 1.
245. See Jane Light, Moves to Stem Decline in Prozac Sales, REUTERS, June 4,
1991 (financial report); See also Daniel Wise, Eli Lilly to Pay Legal Expenses,
Awards to Doctors in Prozac Suits. N.Y.L.J.. June 6. 1991. at 1.
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VIII. IMPROPER INDUCEMENTS, GHOST WRITING IN
SCIENCE JOURNALS, FINANCIAL TIES, AND OTHER
UNETHICAL PRACTICES THAT ERODE PUBLIC FAITH IN
THE PHARMACEUTICAL INDUSTRY
Recently, the United States government has warned pharmaceutical
companies that they must not offer any financial incentives to doctors,
pharmacists, or other health care professionals to prescribe or
recommend particular drugs, or to switch patients from one medicine
to another. 24' The new standards, the first of their kind, were issued by
the inspector general of the Department of Health and Human
Services, as guidance to the medical industry. The purpose of this
directive is to deter the widespread practice of drug companies inviting
physicians to dinner meetings at expensive restaurants, where they are
also paid $500 to $1500 or more to listen to research studies, often paid
for by the pharmaceutical company, and to hear sales pitches regarding
new drugs. The new standards do not have the force of law, but
pharmaceutical firms that flout them are more likely to be investigated
247and prosecuted for violations of federal fraud and kickback statutes.
Many practices commonly used in the marketing and sale of
prescription drugs are thought to run afoul of federal fraud and abuse
248laws. Other practices of pharmaceutical companies discouraged by
the new directive include treating doctors to free Broadway plays,
weekend trips, and paying generous stipends for attending
"educational conferences" at which their drugs are promoted.
Pharmacies have often received payments for putting a company's
products on lists of recommended drugs, known as formularies.
Pharmaceutical companies have routinely rewarded doctors and
drugstores for switching patients from one medication to another, or
from generic drugs to brand-name medicines.
During the public comment period to the government's proposed
regulations, the drug industry, health maintenance organizations, and
doctors have flooded the Department of Health and Human
246. Robert Pear, U.S. Warning To Drug Makers Over Payments, N.Y. TIMES,
Oct. 1, 2002, at Al.
247. Id. Presently, the Food and Drug Administration is reviewing its own
regulations to determine whether it should relax limits on behind-the-scenes
marketing of pharmaceuticals. See Melody Petersen, Madison Ave. Has Growing
Role In the Business of Drug Research, N.Y. TIMES, Nov. 22, 2002, at C4.
248. Pear, supra note 246.
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Resources with letters criticizing the proposal.2 49 They contend that
the proposal constitutes a federal "code of conduct" that would require
radical changes that would be profoundly disruptive to the
pharmaceutical industry. At the same time, pharmaceutical
companies acknowledge that they routinely make payments to
insurance companies to increase the use of certain drugs or add them
to recommended lists, so as to expand their market share, and that
they reward doctors and pharmacies for switching patients from one
drug to another. 50
The drug industry relies substantially more on behind-the-scenes
promotion than on direct advertising. In 2001, just $2.8 billion of the
$11.8 billion spent by the drug industry on marketing was aimed at
consumers, with the remainder going for "educational conferences,"
dinner meetings, and other behind-the-scenes promotions, according
to Verispan, a health-care information firm. 5'
A separate and equally, if not more troubling, concern is the growing
role of advertising agencies in the business of conducting clinical trials
of pharmaceuticals. 212 In the early 1990s, about seventy-five percent of
the drug industry's clinical research budget went to universities,
according to a study by CenterWatch, a firm that tracks clinical trials.5 3
In 2000, by contrast, thirty-four percent went to academic institutions,
with the rest budgeted to investigators working under the auspices of
private research firms that are partly owned by advertising agencies or
2-by firms under the direction of pharmaceutical companies. 4 Some
advertising companies ghost-write articles for medical journals with the
aim of showing that certain drugs have the qualities patients most
desire and to manipulate doctors' prescribing protocols.
5
Only a few years ago, drug research and education were the
province of universities. But with pharmaceutical companies
counting on instant blockbuster sales of their new drugs,
executives found the university system too slow. And ad
agencies - having built a multibillion-dollar business selling drugs
256to consumers - pushed deeper and deeper into the process.
249. See id.
250. See id.







The involvement of advertising agencies now introduces a whole
new bias into clinical trials "so that the American public and the
physicians in the United States are not going to know, really, the true
facts about [new] drugs.",157 Because of aggressive marketing in the
pursuit of huge sales shortly after a drug enters the marketplace,
millions of patients may take a drug before all of its side effects are
known. That is apparently what happened with the bandwagon
attraction to Prozac, before the public learned about the extensive and
serious side effects such as aggressiveness, suicidal ideation, and so
forth, as discussed above.
A further ethical concern is that in 1998 it was reported that eleven
percent of the articles published in the nation's top medical journals,
including The Journal of the American Medical Association, were
ghost-written. 258 One strategy is to ghost-write research and medical
education pieces as a way of promoting drugs before they have
completed the clinical trials and been approved by the FDA in order to
create markets for new drugs long before they gain FDA approval.2 9
In addition, these advertising agencies strive to persuade physicians to
260prescribe drugs for conditions that they are not approved to treat.
"Doctors are led to prescribe drugs that may not be necessarily worth
the money, may not be better than a generic that's already on the
market and that their patients don't need. It's clearly contributing to
the rising costs of prescription drugs and health care.,
261
Apart from the ghost-writing issue, there is a separate ethical
problem involving financial ties of contributors to scientific journals
with regard to products or companies that could benefit from the
articles they write. In some instances, studies that appear in peer-
reviewed journals are financed by drug companies, creating what
appears to be a straightforward conflict of interest. Hidden financial
conflicts have forced the publisher of some of the world's most
influential scientific journals to modify their editorial policies. Nature
257. See Petersen, supra note 247.
25& Id. In a lawsuit against the drug company, Wyeth, it was disclosed that the
company had hired ghostwriters to help promote the diet drug fen-phen after it
became evident that the drug causes a potentially fatal heart-valve deficiency.
Federal and state investigations of Warner-Lambert's marketing of Neurontin, an
epileptic drug, disclosed ghostwriting of journal pieces to market more than a
dozen unapproved uses. Id.
259. Id.
260. Id.
261. Id. (quoting Arnold S. Relman, M.D., professor emeritus at Harvard
Medical School and a former editor of The New England Journal of Medicine).
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Publishing Group, part of the Macmillan Publisher, recently
announced that it would henceforth require its authors to disclose any
262financial ties to the products they evaluate. This new policy has been
implemented at the journal Nature and its sister publications. 263 This
change arose in response to widespread criticism of an article in Nature
Neuroscience in November 2002 which addressed treatments for
depression. The author, Dr. Charles B. Nemeroff, chairman of the
department of psychiatry and behavioral sciences at the Emory School
of Medicine in Atlanta, praised some of the products in which he had
significant financial stakes in three of the therapies he mentioned
favorably.26  It makes ethical sense to require authors of original
research articles to disclose their financial conflicts because industry
financing carries with it the inherent potential to influence and shape
commercial bias. The editors of Nature Neuroscience stated that when
scientists "offer their professional expertise without disclosing
potential financial benefits to themselves, it threatens to undermine
public trust, not simply in a particular paper or journal, but in the
integrity of the scientific enterprise as a whole., 265 Up until now, the
journals required only the authors of articles describing original
research to disclose any financial ties. Other medical journals that
have not yet adopted expansive disclosure rules, or those that have no
policy at all, should proceed to establish appropriate new policies that
are in keeping with the higher ethical standards suggested by the
editors of Nature Neuroscience.
In addition, there are alarming allegations that five of the ten voting
members on the FDA's Psychopharmacology Advisory Committee
(PDAC) that approved Prozac for marketing to the public had
financial ties with the pharmaceutical industry; one of them had done
extensive research on Prozac and received a check from Lilly within a
few days of the vote in which Prozac was approved.266
262. Melody Petersen, Science Journals Tighten Rules For Disclosure of




266. See Cole Complaint, supra note 31, at 31.
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IX. THE FURTHER PROBLEM OF "COSMETIC
PHARMACOLOGY"
One final ethical concern involves the emergence of the field of
"cosmetic pharmacology." With the introduction of Prozac in 1987, the
question of using psychiatric drugs to alter personality in useful,
attractive ways has lost any futuristic tone that it might have once had.
Despite the fact that Prozac has only been approved for use in
clinically depressed patients, bulimia, and obsessive-compulsive
disorder,"' "folks are using it for just about everything but
hangnails. ' '268 Ethical issues become particularly acute when the
patient is one who, all things considered, is "normal." It has been
widely noted that numerous people take Prozac who have never
suffered from depression, because it gives them an "edge" in the
corporate world, with such enhancements as assertiveness, vivacity,
mental acuity, and a "dash of hedonism., 26 9 The ethics of what we
might call cosmetic pharmacology extends to the use not only of
Prozac and other SSRIs for conditions that are not mental disorders,
but to Ritalin, which is used to enhance concentration; beta blockers to
alleviate stage fright; and anticonvulsants for stress.27°
The principal ethical concern here is the propriety of prescribing
drugs for normal patients that can alter their very conception of self.
One of the consequences of the "cosmetic" use of such drugs is that
more and more people might be convinced or in a way compelled to
jump on the bandwagon so as to maintain parity in competition. If a
rival in one's firm seems to be enjoying a certain mental acuity and
assertiveness hitherto dormant and now bolstered by Prozac or similar
drugs, one might feel at a disadvantage unless one joins suit. A similar
pressure developed in the early 1980s, prior to drug testing for steroids
in professional athletics. As one football player commented on the use
of steroids in his sport: "Every team was looking for an edge." '271
There was "an inherent coerciveness present in these situations: when
some choose to do what gives them a competitive edge, others will be
pressed to do likewise, or resign themselves to either accepting a
267. Cebuliak, supra note 110, at 612.
268. Geoffrey Cowley, The Culture of Prozac, NEWSWEEK, Feb. 7, 1994, at 41.
269. Cebuliak, supra note 110, at 620.
270. Id. at 619.
271. T. H. Murray, Drugs, Sports and Ethics, in FEELING GOOD AND DOING
BETrER: ETHICS AND NONTHERAPEUTIC DRUG USE 115 (Thomas H. Murray et al.
eds., 1984).
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competitive disadvantage, or leaving the endeavour entirely., 21 It is
not difficult to see how this same inherent coerciveness might well
involve an employee who feels pressure to be as aggressive and
confident as others in the workplace or marketplace.
The very concept of "normal" could well be ratcheted up, and
perhaps that has already happened, based on evolving cultural norms
associated with mood enhancing drugs. "Prozac highlights our culture's
preference for certain personality types.., by allowing people to move
toward a cultural ideal - the flexible, contented, energetic, pleasure
driven consumer. 2 73  If more and more people clamor for
enhancements in order to feel a certain way, they may come to regard
certain states of aggressiveness or imperviousness to disappointment as
"normal," which could turn psychiatry on its head.
Perhaps cosmetic pharmacology is the inevitable wave of the future.
As the ranks in the business world are filled with new breeds of
personality, the playing field likely would ratchet up quite
dramatically, and the popularity of various personality traits might
increase as well. One can imagine a pharmacological battle of sorts,
with consumers pushing for stronger "free enterprise" personality
traits. If a large number of people opt to select for "cosmetic
pharmacology" there could be an overabundance of these similar
personalities. If so, we would live in a strange new world in which
everyone could or would be a highly aggressive individual with the
same personality traits.
When science enters a new domain, it becomes necessary for the
language of rights to likewise undergo a paradigm shift, or else explain
its theory consistent with technological advance, and I believe
philosophers are doing so. Technology is a tool for expanding human
potential, to permit greater freedom, not the limiting of freedom.174 I
suggest that we examine the ethical concern over "cosmetic
pharmacology" from the following standpoints:
A. The Impact on Individuality and Human Dignity
John Stuart Mill said that because of the need for self-expression
that follows upon the capacity for thought and reflection, human
beings simply cannot be made happier by external constraints on our
272. Id. at 116 (emphasis in original).
273. PETER D. KRAMER, LISTENING TO PROZAC: A PSYCHIATRIST EXPLORES
ANTIDEPRESSANT DRUGS AND THE REMAKING OF SELF 270-272 (1993).
274. Changing Your Genes, THE ECONOMIST, Apr. 25, 1992 at 11, 12.
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development and spontaneity, however benevolent these external
275constraints might be. If people's personalities have been determined
by pharmacological aids they may encounter a loss of a normal sense
of individuality and self, or the freedom to create their own identity.
Some people might feel "inauthentic"-that there is no real "self" for
them to be because their personality has been fixed or altered by a
drug. One consequence of a pharmacological society is, as Carl R.
Rogers said, "depersonalizing them, controlling them by means so
carefully selected that they will perhaps never be aware of their loss of
personhood. '27 6 If people can select personality traits, this could lead
to a market model which would put a price on all human
characteristics, thereby commodifying human beings.
B. The Problem of Free Will
It is a fundamental notion of liberty that human beings make their
own decisions about their lives. This theory is expressed in the
Constitution,27' and it is a principle found in Locke's proposition that
everyone has the "equal right. . . to his natural freedom, without being
subjected to the will or authority of any other man. 2 7 ' This
underscores the importance of liberty in our capacity for self-
211expression. If patients are in effect programmed to develop a
personality set, this could undermine the conception of free will. What
is to be said of the status of free will if people are in effect
programmed to behave in a particular way? If people's personality
traits are causally determined, we may need to re-examine traditional
notions of free will.
275. See John Stuart Mill, On Liberty, in THE UTILITARIANS 483-84 (Doubleday
Books 1973).
276. Quote of Carl R. Rogers, former president of the American Psychological
Association, in What is Psychiatry doing at this very moment in the year 2002?,
available at http://www.prozactruth.com/index (last visited Feb. 8, 2004).
277. See David A.J. Richards, The Individual, The Family, and the Constitution:
A Jurisprudential Perspective, 55 N.Y.U. L. Rev. 1, 6, 8 (1980).
278. JOHN LOCKE, SECOND TREATISE ON GOVERNMENT § 54, at 31 (C.B.
Macpherson, ed. 1980) (1690).
279. See Mill, supra note 275, at 484.
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C The Problem of Fairness
A system of "cosmetic pharmacology" could promote various types
of personality advantages. Would this be unfair to people who had
worked their way towards these goals rather than popping a pill? On
the other hand, some people, because of pharmacological advantages,
might not develop virtues such as perseverance, determination,
aggressiveness, and so on - and may be disadvantaged in the areas of
life where these skills come into play.
D. The Problem of Equal Distribution
As many people start using "cosmetic pharmacology" to produce
better personality traits and other behavioral advantages, people who
are not able to afford its use could become severely disadvantaged.
This could pose significant problems in our otherwise egalitarian social
structure, with a group of privileged individuals on Prozac pitted
against those who cannot afford it. People would no longer believe
that they have just as good an opportunity to succeed as the next
person. The enhanced would tend to monopolize desirable
occupations and fill high status social roles. The disadvantaged would
no longer be able to count on traditional methods of social
advancement, such as hard work or perseverance, to improve the
quality of their lives. By giving an unfair advantage to enhanced
individuals, we would undermine the principle of social equality, and
the idea in the Declaration of Independence that "all men are created
equal" would seem to be simply false.
If health insurance coverage of today's technology is any indication,
"cosmetic enhancement" will not be covered by most insurance
policies. Cosmetic surgery, in vitro fertilization, fitness centers,
performance enhancing drugs, and other technological advantages in
life are paid for by the individuals involved. Thus, "cosmetic
pharmacology" can exacerbate social and economic inequalities unless
these drugs are made available to everyone at an affordable cost.
The use of Prozac and other psychiatric drugs to treat clinical
depression and other mental disorders is a medical breakthrough of
great value to many who suffer from serious mental illness. But its use




Bruno Bettelheim, in his study "The Uses of Enchantment," said
that a struggle against severe difficulties in life is unavoidable, that it is
280an intrinsic part of human existence. In other words, life is difficult.
There are certain evolutionary and practical utilities to such "negative"
emotions as sadness, depression, grief, and shame. Sadness over
something in one's midst pushes one to look at, appreciate, and
understand interpersonal causal connections; if sadness is caused by
the loss of a loved one, one's bond is seen as something that matters; if
there is no sadness over the loss of a loved one, there would be little
survival motivation to stick with a mate, partner, or other loved one.
Many other examples might be elicited as to the worth of "unwanted"
emotions. One commentator notes that in American society it is seen
as abnormal to express grief beyond one year after the death of a loved
one, while in rural Greece, formalized grief customarily extends for
five years.28' Unlike Americans, those in rural Greece have a high level
of affect tolerance, which refers to the ability to endure what one
feels.28
Psychiatry no longer seems to encompass such things as awareness,
attention, intention, imagination, and concentration, or to develop
techniques to aid patients in strengthening their use and control of
these faculties. Psychiatry seems to have obliterated its mission to aid
patients in investigating the actual source of the problems they
experience with their own mind. Psychiatrists increasingly seem to
back away from engaging in the endeavor of empowering or
strengthening the capabilities of patients, and instead opt for
psychiatric drugs.
Many patients who have taken antidepressants or other psychiatric
drugs have found that the medications, while helpful, have not solved
their problems in forming intimate relationships, in avoiding
destructive behavior patterns, or in overcoming other pervasive
personality problems. In an era of managed care, in an era when time
is often a bigger issue than money, in an era when mental health
professionals are perceived as "arrogant," "elitist," "uninvolved,"
280. BRUNO BETrELHEIM, THE USES OF ENCHANTMENT: THE MEANING AND
IMPORTANCE OF FAIRY TALES (1976).
281. Cebuliak, supra note 110, at 621 n.83.
282. Id. at 400.
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"cultish," and "insular, 28 3 psychiatry has been transformed into an
institution with a split personality of its own. The function of
psychiatry seems to have moved far away from aiding the patient to
investigate the nature and potential of one's inner and invisible mental
activity. Has America become a nation where painful emotions are
classified as a mental illness that can only be treated with
pharmaceuticals? Such a philosophy casts aside traditional notions of
self and puts the very idea of self into disarray. For such users, where
is the true self to be found? Ought psychiatry to be in the business of
muting all negative emotions? Does Prozac really transform a person's
life into a happy one in the full sense intended by philosophers such as
Aristotle?
Aristotle emphasized the importance of self-perfection, self-mastery,
and human excellences in connection with human flourishing. One
may have the feeling of happiness without really being happy in a full-
blown, authentic, objective sense. A person may be induced into a
sense of happiness by self-deception, but if external facts, such as the
activities in one's life, are not constitutive of human excellences, the
feeling of happiness will be counterfeit, inauthentic, and something
that can be easily disappear. Whether a person is or is not happy
depends on whether the person is living a life of virtue, of human
excellences, and that is something we can evaluate from an objective
standpoint. Thus, from Aristotle's perspective, feeling good is not
necessarily equated with being happy so that it would be contrary to a
good life to medicate away life's ordinary feelings that emerge from
the little disappointments and setbacks that we experience, feelings
that often enough propel us to look inward, to know ourselves better,
and to become more authentic human beings as a result of such
contemplation.
Psychotherapy, brain physiology, and philosophy have become
increasingly interlinked. Psychoanalytic treatment attempts to unlock
the sexual and aggressive conflicts presumed to underlie the frightful
nature of the unwanted thoughts and action. A point now widely
accepted by most psychoanalysts is that psychotherapy rarely works
for obsessive compulsive disorder, which encumbers "patients with
unwanted thoughts, often violent or sexual, that play in the mind like a
broken record," nor with other serious mental disorders such as
psychopathy and paraphilias2 8 Furthermore, psychotherapy alone is
ineffective with psychoses such as schizophrenia, where there is strong
283. Erica Goode, Even in the Age of Prozac, Some Still Prefer the Couch, N.Y.
TIMES, Jan. 28, 2003, at D1.
284. Friedman, supra note 16, at D5.
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evidence of structural, as well as functional, brain abnormalities. In
cases where the brain is severely damaged or abnormal, talk therapy
cannot cure the patient or modify the patient's behavior.
Clearly patients who do best on SSRIs are those who receive
psychotherapy along with the medication. 5  Prozac seems to be
appropriate in the treatment of various mental disorders, but only in
conjunction with supervised psychotherapy. The majority of people
taking Prozac are not getting any psychotherapy and obtain the
prescription from their family doctors. Thus, the root causes of the
depression, anxiety, or other symptoms are in effect ignored,
suppressed, and not authentically dealt with.
If psychiatric drugs are routinely administered as a substitute for
analysis of a patient's underlying pain, and especially if such drugs are
used purely for cosmetic purposes or for the purpose of merely
enhancing a patient's performance or behavior, then there are serious
ethical concerns. Pharmacology misses the point that caring for a
patient ought to be done in a human, interpersonal basis, rather than
through the sterile and impersonal mode of medication. Many people
think that psychotherapy is preferable to pharmacotherapy because it
is more "natural" and because it strives to get to the root of the
patient's problem. They are convinced that self-understanding will
bring relief, whether the problem is anxiety, depression, or obsessive
compulsive disorder. I believe that any well-being achieved without
the hard work of psychotherapy runs the risk of being artificial and
inauthentic. I believe it is important to examine the source of one's
happiness, what constitutes it, since happiness can be authentic only if
it corresponds with external reality as compared to inauthentic, drug-
induced means.
To some extent the medicalization of psychiatric patients has been
motivated by economic concerns, since states no longer are willing to
allocate significant resources to mental hospitals, and privatizing the
care of many of these patients is impossible because psychiatrists
cannot make money off of this kind of business. In addition, the
impact of managed care and the growing popularity of shorter forms of
psychotherapy, and the unprecedented targeted advertising campaign
for antidepressants, coupled with the even more costly behind-the-
scenes marketing of drugs to physicians, reflect the marked shift/ • 287
towards psychiatric pharmacology. The future of psychiatry can be
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seriously jeopardized by a culture of pharmacology and medical
insurers pushing for immediate results and who are unwilling to cover
complete treatments consisting of a combination of drug and talk
therapy. Psychiatrists themselves may be pressured to give up the
couch because fewer and fewer people may believe that it is worth
their time and money when new and better drugs are available to
eradicate all their emotional problems.
The ethical treatment of psychiatric patients is of international
concern. The Declaration of Hawaii, which was enacted at the General
Assembly of the World Psychiatric Association in 1997, states in its
preamble: "Since the psychiatrist is a member of society as well as a
practitioner of medicine, he or she must consider the ethical
implications specific to psychiatry as well as the ethical demands of all
physicians and the societal responsibility of every man and women.
'288
This statement emphasizes the ethical need for psychiatrists to look to
the political and societal consequences when Prozac or other mood
enhancers are used to transform the personalities of "normal"
individuals. In this regard, section seven of the Declaration states:
"The psychiatrist must on no account utilize the tools of his profession,
once the absence of psychiatric illness has been established." 9 Under
this protocol, in all cases Prozac is inappropriate when prescribed to
those who are diagnostically classified as "normal."
On the other hand, in a society that places a high value on individual
freedom, it is hard to find any legitimate basis for restricting the use of
cosmetic pharmacology. Roscoe Pound suggested that law should
reflect the "received ideals" of the "time and place."2'9 If people
believe that in our time and place the "received ideals" of our culture
endorses and approves of cosmetic pharmacology, lively debates on
the issue would likely seem to persist. In terms of the ramifications on
quality of life, psychiatric pharmacology can make life easier for many
people. Psychiatric pharmacology can provide people with settled
states of tranquility and a feeling of well-being and certain manifested
personality traits that people generally agree are important for success
in the business and social world. If antisocial behavior can be
eliminated by taking a pill, what interest could society possibly have in
restricting such pharmacology? At the same time, it may be
disquieting to think that the evolution of mankind would end up being
reduced to a marketplace agenda in which consumers clamor for more
and better pharmacological enhancements to expand their personality
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potential rather than to seek and celebrate each one's unique and
autonomous path towards self-knowledge.
As Plato says in his Gorgias, routine cooking is distinguished from
medicine. Cookery operates in an entirely untheoretical way, while
medicine involves investigation of the nature of the person whom it
treats and the causes of the symptoms, and can give an account of
these things:
[I]n my opinion cookery differed from medicine in being, not an
art, but a routine, pointing out that the other, that is, medicine,
has investigated the nature of the subject it treats and the cause
of its actions and can give a rational account of each of them,
whereas its counterpart, which is exclusively devoted to
cultivating pleasure, approaches it in a thoroughly unscientific
way, without once having investigated the nature of pleasure or
its cause; and without any pretense whatever to reason and
practically no effort to classify, it preserves by mere experience
and routine a memory of what usually happens, thereby securing
its pleasures. 91
A thought experiment suggested by the philosopher Robert Nozick
appears appropriate here. Imagine being plugged into a theoretical
"pleasure machine" that provides you with a "virtual reality"
experience of fulfilling your ambitions, dreams, and aspirations or
whatever you desire for happiness. You might feel happy, but these
experiences would be no more than dreams playing out in a virtual
reality theatre of brain waves and would not manifest in the real world.
Would you want to live your life that way? My view on this is that it
would seem odd if pleasures or the feeling of happiness are not
connected to real life experiences, for as a species we value real
experiences. A good life seems to be one that engages and makes use
of rational capacities. Someone looking at me hooked up to the
machine would see something analogous to someone in a persistent
vegetative state - to the objective observer I am a pitiful creature
whose quality of life is bleak, whose well-being is nil. I will simply be
experiencing a succession of pleasurable dreams and adventures, all
the while being oblivious to the reality of my hibernation.
Life, after all, consists of much more than feeling good. In life
pleasure is associated with the attainment of real goals. A happy life
is one that entails the normal engagement of plans, risks, failures - an
inclusive notion of well-being that contemplates a pluralism of things
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that are of value - not only feeling good, but living a moral life, having
an active sense of agency, really having freedom.
As mentioned above, Aristotle takes it that an assessment of
whether one is or is not happy is an objective matter, based on
evidence that the inner and outer state of affairs in our lives, both our
psychological attitude and the doings of our lives, correspond. The
external facts about our lives must be objectively good in order for
happiness to be authentic, rather than be predicated by being hooked
up to a pleasure machine. We can have a tranquil state of mind
whether or not we are doing well in life, simply by a taking an ample
amount of the right kind of drug to generate a burst of the brain
chemical, dopamine, or to have hypnosis, and so on. The pleasure
machine emphasizes pleasure as an end in itself to the preclusion or
exclusion of all other ends. There is a certain loss of honor, of dignity,
in engaging in such a scheme. How can we say the person in the
pleasure machine has well-being or is happy? There may be a
chimera-like state of well-being, but little reflection is needed to see
that the person's state of happiness is flawed because it lacks objective
criteria.
